[COMPANY_001] Global Medical Affairs
QAW039
Clinical Trial Protocol CQAW039A2322 / [STUDY_ID_REMOVED]
A multicenter, randomized, double- blind, parallel -group, 
placebo -controlled study of fev ipi[INVESTIGATOR_626194] -of-care (SoC) for assessment of the efficacy in 
reduction of nasal poly ps size in patients w ith nasal 
polyposis and concomitant asthma
Document type: Amended Protocol Version
EUDRACT number: 2018 -002073 -22
Version number: 03 (Clean )
Clinical Trial Phase: III
Release date: 24-Sep-2019
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template version 1.0 dated 01 -Dec-2017

[COMPANY_001] Confidential Page 2
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Table of contents
Table of contents ................................................................................................................. [ADDRESS_834461] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Amendment 3 .................................................................................................................... 12
Amendment 2 .................................................................................................................... 13
Amendment 1 .................................................................................................................... 14
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 18
1.1 Background ............................................................................................................ 18
1.2 Purpose .................................................................................................................. 19
2Objectives and endpoints ................................ ................................ ................................ ...19
3Study  design ...................................................................................................................... 20
4Rationale ................................ ................................ ................................ ............................ 20
4.1 Rationale for stud y design ..................................................................................... 20
4.1.1 Rationale for choice of background therap y
......................................... 21
4.2
Rationale for dose/regimen and duration of treatment .......................................... 21
4.3
Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 21
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..21
4.5 Risks and benefits .................................................................................................. 22
5Population .......................................................................................................................... 24
5.1 Inclusion criteria .................................................................................................... 24
5.2 Exclusion criteria ................................................................................................... 24
6Treatment ........................................................................................................................... 28
6.1 Study  treatment ...................................................................................................... 28
6.1.1 Investigational and control drugs .......................................................... 28
6.1.2 Additional study  treatments .................................................................. 28
6.1.3 Treatment arms/group ........................................................................... 28
6.1.4 Treatment duration ................................................................................ 29
6.2 Other treatment(s) .................................................................................................. 29

[COMPANY_001] Confidential Page 3
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
6.2.[ADDRESS_834462] demographics/other baseline characteristics............................................. 39
8.3 Efficacy .................................................................................................................. 39
8.3.1 Nasal Poly p Score ................................................................................. 40
8.3.2
Patient Reported Outcomes................................................................... 40
8.3.3 Smell (UPSIT) ....................................................................................... 41
8.3.4 Appropriateness of efficacy  assessments .............................................. 41
8.4 Safety ..................................................................................................................... 41
8.4.1 Laboratory  evaluations .......................................................................... 42
8.4.2 Electrocardiogram (ECG) ..................................................................... 42
8.4.3 Pregnancy .............................................................................................. 43
8.4.4 Appropriateness of safety  measurements .............................................. 43
8.5
Additional assessments.......................................................................................... 43
8.5.1 Clinical Outcome Assessments (COAs) ............................................... 43

[COMPANY_001] Confidential Page 4
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
[ADDRESS_834463] -study  treatment .......................................................... 47
10Safety  monitoring and reporting ................................ ................................ ........................ 47
10.1 Definition of adverse events and reporting requirements ...................................... 47
10.1.1 Adverse events ...................................................................................... 47
10.1.2 Serious adverse events .......................................................................... 49
10.1.3 SAE reporting
........................................................................................ 50
10.1.4 Pregnancy  reporting .............................................................................. 50
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ [ADDRESS_834464] demographics and other baseline characteristics...................................... 55
12.3 Treatments ............................................................................................................. 55
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 55
12.4.1 Definition of primary  endpoint(s) ......................................................... 56
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 56
12.4.3 Handling of missing values/censoring/discontinuations ....................... 57
12.4.4 Sensitivity  and Supportive anal yses...................................................... 57
12.5 Analy sis of secondary  endpoints ........................................................................... 58
12.5.1 Safety  Variables .................................................................................... 59

[COMPANY_001] Confidential Page 5
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
60
12.7 Interim anal yses..................................................................................................... 60
12.8
Sample size calculation.......................................................................................... 61
12.8.1 Primary  endpoint(s) ............................................................................... 61
13Ethical considerations and administrative procedures ...................................................... 61
13.1 Regulatory
 and ethical compliance ........................................................................ 61
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 61
13.3 Publication of study  protocol and results ............................................................... 62
13.4 Quality  Control and Quality  Assurance ................................................................. 62
14Protocol adherence ............................................................................................................ 62
14.1 Protocol Amendments ........................................................................................... 63
15References ......................................................................................................................... 64
16Appendices ................................ ................................ ................................ ........................ 66
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 66
16.2 Appendix 2: L iver event and Laboratory  trigger Definitions and Follow-up 
Requirements ......................................................................................................... 67
16.3
Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow -up...... 69
16.4 Appendix 4: Nasal Congestion Score Questionnaire............................................. 70
16.5 Appendix 5: SNOT -22 Questionnaire ................................................................... 71
16.6 Appendix 6: ACQ -[ADDRESS_834465] ionnaire ....................................................................... 72
16.7 Appendix 7: Nasal Endoscopy
............................................................................... [ADDRESS_834466] of tables
Table 1-1 Nasal Poly p Scale .................................................................................. 18
Table 2
-1 Objectives and related endpoints ................................ .......................... 19
Table 6-1 Medications allowed under certain conditions ...................................... 29
Table 6
-2 Prohibited Medication................................ ................................ ........... 30
Table 6-3 Blinding and unblinding plan................................ ................................ 32
Table 8-1 Assessment Schedule ............................................................................ 37
Table 8
-2 Nasal Poly p Scale ................................ ................................ .................. 40
Table 8-3 Physical Assessments ............................................................................ 41
Table 8
-4 Laboratory  Assessments ................................ ................................ ........ 42
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 51

[COMPANY_001] Confidential Page 6
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Table 16-[ADDRESS_834467] Hy potheses ................................ ..56
Figure 16 -1 Nasal Congestion Score ........................................................................ 70
Figure 16 -
2 SNOT- 22 Questionnaire ................................ ................................ ........ 71
Figure 16 -3 Asthma Control Questionnaire - 5 - Page 1 .......................................... 72
Figure 16 -
4 Asthma Control Questionnaire - 5 - Page 2 .......................................... 73

[COMPANY_001] Confidential Page 7
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
List of abbreviations
ACQ -[ADDRESS_834468] aspartate aminotransferase
ATC anatomical therapeutic chemical
AUC area under the curve
AV atrioventricular
BMI body  mass index
BSACI British society for allergy and clinical immunology
BUN blood urea nitrogen
CFR code of federal regulation
CK creatinine kinase
Cmax maximum concentration
COAs clinical outcome assessments
CPO country pharma organisation
CRA clinical research associate
CRF case report/record form (paper or electronic)
CT computerized tomography
CTT clinical trial team
DAR dose administration record
DMC data monitoring committee
DP2 prostaglandin D2 receptor
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
eGFR estimated glomerular filtration rate
EMA European medicines agency
ENT ear, nose, throat
EOT end of treatment
EU European Union
FAS full analysis sets
FCT film-coated tablets
FEV1 forced expi[INVESTIGATOR_13521] y volume in 1 second
FVC forced vital capacity

[COMPANY_001] Confidential Page 8
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
GCP good clinical practice
GGT gamma -glutam yl-transferase
GINA global initiative for asthma
HbA1c hemoglobin A1c
IB Investigator's brochure
ICH international conference on harmonization of technical requirements for registration of 
pharmaceuticals for human use
ICS inhaled corticosteroids
IDR idiosyncratic drug reactions
IEC independent ethics committee
IgE immunoglobulin E
IL5 interleukin [ADDRESS_834469]
NP nasal polyposis
NPS nasal polyp score
NYHA [LOCATION_001] Heart Association
OAT organic anion transporter
OATP organic anion transporting polypeptide
OCS oral corticosteroids

[COMPANY_001] Confidential Page 9
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
P-gp P-glycoprotein
PASS power analysis software
PCR protein -creatinine ratio
PK pharmacokinetic
PRO patient -reported outcome
PT prothrombin time
QMS qualit y managem ent system
QoL qualit y of life
QTc QT interval
QTcF QT interval - Fridericia correction
RoW rest of world
SABA short -acting bronchodilator
SAE serious adverse event
SAF safety analy sis set
sCr serum creatinine
SCS systemic corticosteroids
SD standard deviation
SNOT -
22sino-nasal outcome test -[ADDRESS_834470]
US [LOCATION_002]
USB universal serial bus
WHO world health organization
WoC withdrawal of consent

[COMPANY_001] Confidential Page 10
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A specific group of subjects fulfilling certain criteria
Control drug Any drug (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the investigational drug being tested in the trial
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)
Enrollment Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Epoch Interval of time in the planned co nduct of a study. An epoch is associated 
with a purpose (e.g. screening, randomization, treatment, follow -up), which 
applies across all arms of a study.
Investigational drug The study drug whose properties are being tested in the study; this definition 
isconsistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug” or “test substance”
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the study as 
well as their associated treatment controls. This includes any placebos, any 
active controls, as well as approved drugs used outside of their 
indication/approved dosage or tested in a fixed combination. Investigational 
treatment generally does not include other treatmen ts administered as 
concomitant background therapy required or allowed by [CONTACT_331985]/dosage.
Medication number A unique identifier on the label of each study drug package in studies that 
dispense study drug using an IRT sy stem.
Non-investigational 
medicinal Product 
(NIMP)Products which are not the object of investigation (e.g. any background 
therapy administered to each of the clinical trial subjects, regardless of 
randomization group, rescue medication, active drug run-ins etc.)
Patient An individual with the condition of interest
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned.
Randomization 
numberA unique identifier assigned to each randomized subject, corresponding to a 
specific treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
Stage A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Study com pletion Point/time at which the subject came in for a final evaluation visit or when 
study drug was discontinued whichever is later.
Study 
drug/treatmentAny drug (or combination of drugs) administered to the subject as part of the 
required study procedures; includes investigational drug, active drug run -ins 
or background therapy.
Study treatment Any drug administered to the study participants as part of the requir ed study 
procedures; includes investigational drug (s), control(s) or non -investigational 
medicinal product(s)

[COMPANY_001] Confidential Page 11
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Study treatment 
discontinuationWhen the subject permanently stops taking study treatment prior to the 
defined study treatment completion date
Subject An individual who has consented to participate in this study. The term 
Subject may be used to describe either a healthy volunteer or a patient.
Subject number A unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject and 
should be used to identify the subject throughout the study for all data 
collected, sample labels, etc.
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study
Withdrawal of 
consent (W oC)Withdrawal of consent from the study is defined as when a subject does not 
want to participate in the study any longer, anddoes not want any further 
visits o r assessments, anddoes not want any further study related contact, 
anddoes not allow analysis of already obtained biologic material

[COMPANY_001] Confidential Page 12
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Amendment 3
Amendment rationale
The protocol is being amended to provide clarification on the process for assessment of nasal 
endoscop y at baseline and management of protocol deviations in relation to the statistical 
analysis sets. These changes include: 
Changes in Section 8.3.1 to remove the constraint around the performance of the nasal 
endoscop y at the end of run-in/baseline visit along with confirming that patient 
eligibility  will be based on the central reading score
Change to the text in Section 12.1 to highlight that the Full Analy sis Set will only 
comprise of patients with a baseline NPS ≥ 4, confirmed by  [CONTACT_18014]
Addition of text in Section 12.4 to clarify  that the central reading score is what will be 
used for the primary  endpoint analy sis
Addition of text in Appendix 7to clarify  that 
the central reading score is the final 
determination of eligibility  at both screening and end of run -in/ba seline. 
IRB Section
The changes described in this protocol have been classed as non-substantial and will not require 
additional I RB/HA approval, unless required by  [CONTACT_427]. 

[COMPANY_001] Confidential Page 13
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Amendment 2
Amendment rationale
The protocol is being amended to align the safety  requirements with other studies in the 
QAW039 program. These changes include:
Addition of exclusion criteria to align with other QAW039 studies in Section 5.2
Update to contraception exclusion criteria to reference that any  local deviations from the 
contraception requirements will apply  and will be described within the patient informed 
consent form. Updates also included to align exclusion criteria with the proh ibited 
medications in Table 6-2
Update to asthma inclusion criteria throughout the protocol to remove reference to Global 
Initiative for Asthma (GINA) Step 3 in order to remove any  contradiction and discrepancy  
with other QAW03
9 trials given this is a new population.
Inclusion of Table 6-1- Medications allowed under certain conditions - in Section 6.2.1
Inclusion of renal safet y monitoring in Section 10.2.2 and additional details as an 
appendix in Section 16.3
Addition of urine pregnancy  testing at each treatment visit
Addition of liver event and renal event monitoring to each visit in Table 8-1
Inclusion of clinical chemistry  reflex testing in the event of elevated creatine kinase (CK) 
results in Table 8-4
Addition of hemoglobin A1c (HbA1c) testing at Screening and end of treatment (EOT) 
with updates to Table 8-1andTable 8-4
Changes to the protocol
The described changes in the aforementioned amendment rationale are implemented throughout 
the protocol in the sections noted. 
The opport unity  was also taken to make the following changes in the protocol:
Changes made in Table 8
-1to clarify  which assessments are performed prior to the start 
of treatment at the Week 1 visit. Other minor clarification changes a lso included in this 
table. 
Addition of patient withdrawal criteria in Section 9.1.1 relating to the need for nasal 
surgery  during the trial, use of corticosteroids during the trial and also for persistent 
muscle pain, wit h or without elevated CK levels. 
Clarification of Nasal Endoscopy readings / assessments being performed centrally  and 
locally
Addition of sensitivity  analy ses in Section 12.4.4
Typographical changes throughout for spell ing/consistency . 
IRB Section
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRB)/Independent Ethics Committee (I EC) and Health Authorities.

[COMPANY_001] Confidential Page 14
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval, a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 
Amendment [ADDRESS_834471] 
been implemented:
Added additional exclusion criteria to Section 5.2 to ensure that patients taking an y of the 
prohibited medications o utlined in Table 6-2are appropriatel y excluded.
Changes to the protocol
The described changes in the aforementioned amendment rationale are implemented throughout 
the protocol in the sections noted.
The opportunity  was also ta ken to amend t
ypographical items in the protocol:
Rewording of the text for the restriction on nasal corticosteroids in Table 6-2to better 
clarify  the specific t ypes that are excluded along with the restricted statin therapie s
Minor revision to the wording in Section
8.3.3

[COMPANY_001] Confidential Page 15
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Protocol summary
Protocol number CQA W039A2322
Full Title A multicenter, randomized, double- blind, parallel -group, placebo -controlled 
study of fevipi[INVESTIGATOR_626195] -of-care (SoC) for assessment of 
the efficacy in reduction of nasal polyp size in patients with nasal polyposis and 
concomitant asthma.
Brief title Study of efficacy of fevipi[INVESTIGATOR_626196] 3b
Investigation 
typeDrug
Study type Interventional
Purpose and 
rationaleNasal polyposis is a common disorder, affecting up to 4% of the population. 
Although the causes remain unclear, nasal polyposis has been associated with 
a numb er of conditions including, asthma, infection, cystic fibrosis and aspi[INVESTIGATOR_59433]. Nasal polyposis with concomitant asthma has a prevalence ranging 
from 2% -66% although it is usually in the region of 30% of those nasal 
polyposis patients who are ref erred to (ear, nose, throat) ENT departments.
The purpose of this study  is to evaluate the efficacy  and safety of fevipi[INVESTIGATOR_105169] [ADDRESS_834472] on symptoms, quality of life and smell via patient -reported outcomes 
in patients with nasal polyposis (NP) and concomitant asthma.
Primary 
Objective(s) In patients with nasal polyps with a polyp size score ≥ 4 at baseline, to 
demonstrate a difference in mean change from baseline in polyp size at 
Week 16, measured by [CONTACT_626218] (NPS, assessed by [CONTACT_626219]), between fevipi[INVESTIGATOR_105169] (150 mg or 450 mg 
once daily, separately) and placebo
Secondary 
ObjectivesTo evaluate the effect on sy mptoms as measured by [CONTACT_626220] (NCS) with fevipi[INVESTIGATOR_105169] (150 mg or 450 mg once daily), compared 
with placebo following 16 weeks of treatment.
To evaluate the effect on quality of life as measured by [CONTACT_384799] -Nasal 
Outcome Test -22 (SNOT -22) with fevipi[INVESTIGATOR_105169] (150 mg or 450 mg once 
daily), compared with placebo following 16 weeks of treatment.
To evaluate the effect on Smell as measured by [CONTACT_626221] (UPSIT) with fevipi[INVESTIGATOR_105169] (150 mg or 
450 mg once daily), compared with plac ebo following 16 weeks of 
treatment.
To evaluate the effect of fevipi[INVESTIGATOR_105169] 150 mg and 450 mg compared with 
placebo in terms of general safety/tolerability following 16 weeks of 
treatment.
Study design This is a Phase 3b, Proof -of-concept study with a rand omized, m ulticenter, 
double -blind, placebo -controlled, parallel -group study design to determine the 
ability of fevipi[INVESTIGATOR_626197]. The study will include: Screening period of 2 weeks to assess eligib ility; 
Run-in period of 4 weeks where patients will utilize mometasone furoate spray 
(200 µg once daily, administered as two 50 µg actuations into each nostril); 
Treatment period of 16 weeks (with visits held every month for study 
procedures) and a Follow -up period of [ADDRESS_834473] dose of study 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
drug to collect additional data for safety variables. Patients will continue to use 
the mometasone furoate SoC throughout the treatment period.
Population The study population will consist of approximately 93 male and female patients 
aged 18 and above, diagnosed with nasal polyposis with nasal polyp size score 
≥ 4 (nasal polyp score, assessed by [CONTACT_626222]) with a minimum score of 
2 in each nostril; and a concomitant diagnosis of asthma.
Key Inclusion 
criteriaWritten informed consent must be obtained before any assessment is 
performed.
Patients aged ≥ 18 years with a diagnosis of nasal polyposis with nasal 
polyp size score ≥ 4 and a minimum score of 2 in each nostril, measured 
by [CONTACT_626223] -
in/Treatment Day 1 (to ensure no reduction in NPS following the use of the 
mome tasone furoate SoC therapy).
Patients with a concomitant diagnosis of asthma for a period of at least 6 
months prior to screening.
Have been on a stable asthma treatment regimen of at least inhaled 
corticosteroids (ICS, any dose), alone for at least 6 months prior to 
Screening or ICS for 6 months prior to Screening with any other required 
inhaled asthma medication (long -acting bronchodilator (LABA), long -acting 
muscarinic antagonist (LAMA)) added at least 6 weeks prior to Screening.
Key Exclusion 
criteriaAsthma exacerbation, within 6 weeks prior to Screening that required 
systemic corticosteroids, hospi[INVESTIGATOR_059], or emerg ency room visit. When 
patients experience an exacerbation between screening and the end of the 
4 week Run -in period, and prior to randomization, they will be considered 
screen failures and can be eligible for re -screening only once the required 
6 weeks pos t-exacerbation window has passed.
Chronic/maintenance use of oral corticosteroids (OCS) defined as any 
continuous use of OCS for a period of 1 month or more within 1 year of 
Screening.
Use of biologics (omalizumab, mepolizumab, reslisumab, dupi[INVESTIGATOR_12458], 
benra lizumab etc., for asthma or any other indications) that has potential to 
interfere/affect asthma or NP disease progression, within 6 months of the 
start of the Run -in period.
Use of medication for sino -nasal s ymptoms (antibiotics with or without 
OCS) withi n 30 days of Screening or during the Run -in period.
Any contra- indications to inhaled or nasal steroids e.g. narrow angle 
glaucoma, or any other as decided by [CONTACT_737].
History of nasal surgery (including polypectom y) within 6 months prior to 
scree ning.
Patients with asthma control questionnaire -5 questions (ACQ -5) ≥ 1.5 at 
Screening
Study treatmentQAW039 150 mg and QAW 039 450 m g once daily
Matching placebo to QAW 039 150 mg and QA W039 450 mg once daily
Efficacy 
assessmentsAssessment of nasal poly p score by [CONTACT_626222]
Assessment of nasal congestion using the nasal congestion score 
questionnaire
Assessment of quality of life using the SNOT -22 questionnaire
Assessment of smell using the university of Penns ylvania smell 
identification test

[COMPANY_001] Confidential Page 17
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Key safety 
assessmentsMedical histor y and phy sical examination
Adverse events (AEs) including serious adverse events (SAEs)
Vital signs
Electrocardiogram (ECG)
Laboratory evaluations (hematology, blood chemistry , urinaly sis)
Pregnancy (female patients)
Data analysis Approximately 93 patients will be randomized in 1:1:[ADDRESS_834474] of care.
Primary Objective:
The primary aim of the study is to evaluate achange in nasal polyp size with 
fevipi[INVESTIGATOR_105169] (150mg or 450mg once daily, separately) as compared to placebo. 
This will be evaluated by [CONTACT_626224]) which is assessed by [CONTACT_626222]. 
The total NPS is recorded as the sum of the right and left nostril scores with a 
range of 0 to 8. A decrease in the NPS is considered a favorable outcome.
The analysis of the primary endpoint will be conducted according to the intention 
to treat principle using the full analysis set (FAS) population and using a mixed 
modelrepeated measures (MMRM) approach.
Secondary Objectives:
Nasal Congestion Score: The change in NCS will be analyzed using an 
MMRM model.
Quality of Life (SNOT -22):The treatment group difference in terms of 
change from baseline at Week 16 in SNOT -22 wi ll be estimated using an 
MMRM model.
Smell (UPSIT): The treatment group difference in terms of change from 
baseline at W eek 16 in UPSIT will be estimated using an MMRM model.
Safety and Tolerability: For all safety analy ses, the safety set will be 
used. A ll listings and tables will be presented by [CONTACT_1570]. Safety 
summaries will be primarily based on on -treatment data with selected 
tables also presented for the all data after the first intake of study  drug, 
while all databased safety data will be li sted. The on -treatment period lasts 
from the date of first administration of study treatment to [ADDRESS_834475] actual administration of any study treatment.
Key words Efficacy  and safety of QA W039, nasal polyp score, nasal congestion score, 
qualit y of life, smell, nasal polyposis, concomitant asthma, female and male 
patients ≥ 18 years

[COMPANY_001] Confidential Page 18
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
[ADDRESS_834476] on symptoms, 
quality  of life and smell via patient -reported outcomes in patients with nasal polyposis and 
concomitant asthma.
Nasal Polyposis (NP) is a common disorder, affecting up to 4% of the population. Although the 
causes remain unclear, NP has been associated with a number of conditions including asthma, 
infection, cystic fibrosis and aspi[INVESTIGATOR_79948] . The polyps themselves are benign lesions 
arising from the mucosa of the nasal cavity , which present typi[INVESTIGATOR_1306] y as single or multiple 
polypoid masses, causing symptoms including nasal obstruction, anosmia, post nasal drip, 
rhinorrhea and, less commonly , facial pain ( Newton andAh- See 2008 ). NP is diagnosed either 
by a clinical examination or more commonly  via nasal endoscop y. Computerized tomograph y 
(CT) scans are useful but do not provide optimal understanding of the disease extension, as the 
polyps can be indistinguishable of the anatom y, so endoscopic direct observation is more 
accurate for diagnosis. Treatment can range from the use of corticosteroid nasal spray s (e.g. 
mometasone furoate) to surgical interventions. It is common for patients to have relapses, 
requiring repeated surgeries.
NP with concomitant asthma has aprevalence ranging from 2%-66% (Orlandi et al 2016), 
usually  considered in the range of 30% of the NP patients for those referred to ENT departments 
(Larsen ); and it is 58% in those patients with a nasal polyps score ≥ 4 
(Bachert et al 2016). 
Nasal polyp score is assessed by [CONTACT_626225] y using the following scale (Gevaert et al 2013):
Table 1
-1 Nasal Poly p Scale
Poly p Score Poly p Size
0 No polyps
1 Small polyps in the middle meatus not reaching below the inferior border of the middle 
turbinate
2 Polyps reaching below the lower border of the middle turbinate
3 Large polyps reaching the lower border of the inferior turbinate or polyps medial to the 
middle turbinate
4 Large polyps causing complete obstruction of the inferior nasal cavity
Prostaglandin D2 (PGD 2) is one of the major prostanoid inflammatory  mediators identified in 
airway  inflammatory  diseases. The PGD 2type 2 receptor (DP2) usually  mediates these pro-
inflammatory  effects. There is evidence that the DP2 pathway  and PGD 2have an effect on NP 
physiopathology :
The in-vitro study  by [CONTACT_626226] -Novo et al showed that in nasal poly ps taken from 10 patients 
there was an increased release of PGD 2. Pre-treatment with IgE/anti -IgE was significantly  
impacted b y pre -incubation with diclofenac. This suggests that in immunologica lly 
activated NP tissue, PGD 2produced by [CONTACT_626227]2 cells 
through a DP2 dependent mechanism ( Pérez -Novo et al 2010).

[COMPANY_001] Confidential Page 19
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
The study  by [CONTACT_626228]2 than mucosa from uninflamed 
nasal cavities from healthy  donors ( Mjösberg etal2011).
It has been shown that the expression of DP2 receptors is associated with the 
pathophy siology  of Chronic Rhinosinusitis along with NP formation 
(Yamamoto et
al2009).
Elevated percentages of mast cells are found in the sino
-nasal mucosa of chronic 
rhinosinusitis patients with NPs ( Shaw et al)when compared to a health y control group.
Fevipi[INVESTIGATOR_105169] (QAW039) is a DP2 competitive antagonist in investigation in severe asthma. It 
exerts its effect by [CONTACT_626229]2 receptors on eosinophils, Th2 and ILC2 cells in the blood 
and tissues; thus, inhibiting migration and activation of these cells into the airway  tissues and 
reducing the release of pro-inflammatory  cytokines (Chevalier et al 2005). It is proposed that 
fevipi[INVESTIGATOR_626198] a suitable treatment for NP. Moreover it's once daily oral regimen could 
increase compliance when compared with the current standard of care of nasal spray s.
1.2 Purpose
A Phase 3b Proof -of-Concept study  to evaluate the efficacy of fev ipi[INVESTIGATOR_105169] (QAW039) (150 mg 
and 450 mg once daily) compared with placebo, as add-
on to mometasone furoate treatment 
standard -of-care (SoC), in reducing endoscopic nasal polyp score (NPS) and nasal congestion 
score (NCS) in adult ( ≥ 18 y ears) patients with na sal poly posis (NP) and concomitant asthma.
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary  objective(s) Endpoint(s) for primary  objective(s)
In patients with nasal polyps with a polyp size 
score ≥ 4, to demonstrate a difference in mean 
change from baseline in polyp size at week 16, 
measured by [CONTACT_626218] (NPS, 
assessed by [CONTACT_626230]), between fevipi[INVESTIGATOR_105169] (150 mg or 450 mg 
once daily, separately ) and placebo.Reduction (in terms of change from baseline to 
week 16) in NPS for fevipi[INVESTIGATOR_105169] (150 mg or 450 
mg once daily, separately) as compared to 
placebo.
Secondary  objective(s) Endpoint(s) for secondary  objective(s)
To evaluate the effect of fevipi[INVESTIGATOR_105169] 150 mg and 
450 mg compared with placebo in terms of 
general safety/tolerabilityAdverse events, ECG, vital signs and laboratory 
analysis following 16 weeks of treatment.
To evaluate the ef fect on Quality of Life as 
measured by [CONTACT_384799] -Nasal Outcome Test 
(SNOT 22) with fevipi[INVESTIGATOR_105169] (150 mg or 450 mg 
once daily), compared with placebo.Increase (in terms of change from baseline to 
week 16) in QoL score for fevipi[INVESTIGATOR_105169] (150 mg or 
450 mg once d aily, separately) as compared to 
placebo.
To evaluate the effect on Smell as measured by 
[CONTACT_626231] (UPSIT) with fevipi[INVESTIGATOR_105169] (150 
mg or 450 mg once daily), compared with 
placebo.Increase (in terms of change from baseline to 
week 16) in Smell score for fevipi[INVESTIGATOR_105169] (150 mg 
or 450 mg once daily, separately) as compared to 
placebo.
To evaluate the effect on symptoms as measured 
by [CONTACT_626232] (NCS) with Reduction (in terms of change from baseline to 
week 16) in NCS for fevipi[INVESTIGATOR_105169] (150 mg or 450 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Objective(s) Endpoint(s)
fevipi[INVESTIGATOR_105169] (150 mg or 450 mg once daily), 
compared with placebo.mg once daily, separately) as compared to 
placebo.
3 Study  design
This is a Phase 3b, Proof -of-concept study  with a randomized, multicenter, double -blind, 
placebo- controlled, parallel -group study design to determine the ability of fevipi[INVESTIGATOR_626199]. The study  willinclude: Screening 
period of two weeks to assess eligibility ; Run-in period of 4 weeks where patients will utilize 
mometasone furoate spray  (200 µg once daily , administered as two 50 µg actuations into each 
nostril); Treatment period of 16 weeks (with vis its held ever y month for study procedures); and 
a Follow -up period of two weeks following the last dose of study  drug to collect additional data 
for safet y variables. Patients will continue to use the mometasone furoate SoC throughout the 
Treatment period. Approximately  93 patients will be enrolled into this study. Please refer to 
Table 8-1for the clinical visit schedule and the details of procedures to be performed at each 
visit.
Figure 3
-1 Study  Schematic
4 Rationale
4.1 Rationale for study  design
The overall purpose of this study is to determine the ability of fevipi[INVESTIGATOR_105169] (150 mg and 450 mg 
once dail y) plus SoC (mometasone furoate 200 µg dail y), compared with placebo plus SoC, to 
reduce the size of nasal polyps during a 16 week Treatment period, assessed by [CONTACT_626225] y 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
with central reading. The study  will also determine if fevipi[INVESTIGATOR_105169] (150 mg and 450 mg once 
daily ) plus SoC, compared with placebo plus SoC, can reduce symptoms and improve quality 
of life and smell, assessed via patient -reported outcomes (PROs) and the UPSI T.
4.1.[ADDRESS_834477] of care for nasal polyposis as per British society  for allergy 
and clinical immunology  (BSACI) treatment guidelines and will be utilized throughout the 
study , from the start of Run-in until the completion of treatment.
4.2 Rationale for dose/regimen and duration of treatment
QAW039 will be administered at doses of 150 mg and 450 mg once daily as oral film-coated 
tablets (FCTs) in this study . These doses have been selected for the ongoing asthma trials and 
are based on the following rationale:
The 450 mg once daily  dose was selected because at a dose of 450 mg once daily, > 98% 
receptor occupancy is expected at stead y state allowing inhibition of eosinophil migration over 
the entire treatment interval. Meanwhile in Study  [CQAW039A2208] , QAW039 caused 
significant reduction of sputum eosinophils in patients with severe eosinophilic asthma. The 
reduction in sputum eosinophils was comparable to that observed with the anti -IL5 antibodies, 
mepolizumab ( Pavord et al 2012) and reslizumab ( Castroet al2011 , Castro et al 2015 ).
A lower dose of [ADDRESS_834478] dose of QAW039 
with “maximal efficacy” on the endpoint of FEV1 in a prior dose-ranging study  (Study 
[CQAW039 A2206] ) in patients with moderate -to-severe asthma (GINA treatment steps 4 and 
5) as add -on to low -dose ICS. This dose is ½ log lower than the highest dose.
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
All patients in thi s study  will receive mometasone furoate nasal spray  (MFS) as SoC treatment 
with QAW039 or placebo administered as an add -on therap y. Patients currentl y using nasal 
corticosteroid drops or lavage will transfer on to MFS at the start of the Run -in period.
The use of placebo will permit the assessment of a reduction in nasal poly p score (NPS) along 
with improvement in symptoms, quality  of life (QoL) and smell for patients treated with 
QAW039, in comparison to those on placebo, who will be on the nasal poly posis SoC therapy 
only. Additionall y, the use of placebo will permit a controlled evaluation of the safet y of 
QAW039.
This study  does not include an active comparator since QAW039 will be given as an add -on 
therap y to standard of care therap y in patients with a NPS ≥ 4.
4.4 Purpose and timing of interim analy ses/design adaptations
Not applicable as no interim analy sis will be performed on this study .

[COMPANY_001] Confidential Page 22
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
4.5 Risks and benefits
QAW039 is a potent and highly selective oral DP2 receptor antagonist being developed as 
a potential therap y treatment for patients with severe asthma. DP2 is a receptor for PGD 2,
which mediates the activation and migration of Th2 cells and eosinophils, some of the key  
inflammatory  cell ty pes in asthma. Recruitment of these cells into the lung i s partly  
responsible for the intermittent airway  obstruction, which leads to wheezing and shortness 
of breath characteristic of asthma.
QAW039 is at least 300-fold selective for the DP2 receptor compared to other available 
prostanoid receptors and to cy clo
oxygenase -1 and cy clooxy genase -2, and it has been 
demonstrated to be a potent in-vitro inhibitor of human whole blood eosinophil 
activation and induction of Th2 cy tokines. After oral dosing in rats, QAW039 inhibited 
pulmonary  eosinophilia induced by  [CONTACT_339483] D2metabolite DK -PGD 2.
The potential benefits of QAW039 therapy need to be balanced against its potential risks. 
The risk to patients in this study  will be minimized by  [CONTACT_201046]/exclusion criteria and close clinical monitoring. All pat ients will remain on the 
background SoC asthma therap y the y were taking at screening throughout the study.
Women of child- bearing potential and sexually  active males will be informed that taking 
the study  treatment may  involve unknown risks to the fetus if pregnancy  were to occur 
during the stud y, and agree that in order to participate in the study they must adhere to the 
contraception requirements outlined in the exclusion criteria. If there is any  question that 
the patient will not reliably  compl y, they should not be entered or continue in the study .
The overall clinical experience with QAW039 includes 12 studies: 10 (6 in healthy  
volunteers and 4 in patients) have completed and 2 (in patients) are ongoing. The 
completed phase [ADDRESS_834479] of 3 in patients with asthma and 1 in patients with 
allergic rhinitis. The ongoing Phase 2 studies include one study  in patients with asthma 
([CQAW039A2214] ) and 1 study in patients with atopic dermatitis ( [CQAW039X2201] ).
QAW039 has been well tolerated in populatio ns studied to date at total daily doses up to 
[ADDRESS_834480] been no adverse events of idiopathic drug reactions.
Cardiovascular risks: Transient, increases in heart rate were observed in a cardiovascular 
safet y pharmacology study  in dogs. These changes were not associated with any  
significant alterations in blood pressure, ECG interval duration, morphology  or rhy thm or 
any structural changes in cardiac tissues. No cardiac findings have been identified in the 
healthy  volunteer and patient studies completed to date apart from an observed imbalance 
in the frequency  of post -randomization cardiac adverse events in study  
[CQAW039A2206] with a higher incidence in the QAW039 treatment group (1.7%) 
compared with either placebo (0.7%) or montelukast (0%) treated patients. The cardiac 
events comprised a number of different non -serious arrh ythmias and one serious adverse 
event of pericarditis not suspected to be related to study  drug b y the Investigator. Three of 
the events in the QAW039 treatment groups occurred during the washout period and 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
resolved on treatment. Based on the inability to identify  discernable trends with QAW039 
dose, regimen, time -of-onset, patient age and gender, concomitant medication, event ty pe 
and following detail ECG review, it was considered that these were most probably  
coincidental events without a causal assoc iation to study  drug. A formal QTc study  has not 
been completed for QAW039. Monitoring for changes in vital signs, ECGs and 
biochemical parameters will be conducted.
Liver toxicity :Dose -dependent increases in liver weights with concomitant hepatocellular 
hypertrophy  were the primary  findings during 2- and [ADDRESS_834481] not been identified in the h ealth y 
volunteer and patient studies completed to date. Monitoring of liver function tests (LFTs) 
will be conducted as described in Section 16.2 of this protocol.
Potential risk of idiosy ncratic drug reactions CCN362 is an a cylglucuronide metabolite of 
QAW039 and its potential to covalentl y bind to plasma proteins, such as albumin, was 
demonstrated in the human ADME (Absorption, distribution, metabolism, excretion) 
study  of QAW039 ( [CQAW039A2104] ). In the literature, in vivo binding of acy l 
glucuronides to proteins has been reported to be associated with rare idiosyncratic drug 
reactions (IDRs), although a causal connection of protein adduction to IDRs remains 
uncertain ( Regan et al 2010 ). There have been no IDRs observed with QAW039 treatment 
in completed clinical trials. Surveillance of adverse events for identification of IDRs will 
be conducted.
Drug -drug interactions: QAW039 and CCN362 did not show any  relevant inhibition or 
induction of the cy tochrome P450 isoenzy mes or inhibition of ubiquitous efflux 
transporters. The most potent in- vitro inhibition by  [CONTACT_105303]039 was found for OATP1B1, 
but clinically  only a small impact was observed at 450 mg/day  (~2-fold increase in Cmax 
of simvastatin aci d and rosuvastatin without change in AUC). Based on these data, as well 
as recommendations in the simvastatin label, simvastatin doses of > 20 mg per day  should 
not be co-administered with QAW039; no relevant impact on the disposition of other co-
medicatio ns are expected with QAW039 dosed up to 450 mg/day . Patients on doses of 
simvastatin > 20 mg, doses of atorvastatin > 40 mg, doses of pravastatin > 40mg, or doses 
of pi[INVESTIGATOR_2830] > 2 mg per day  (Elsby [CONTACT_2297]2012 , Deng et al 2008, Noé etal2007 , and 
Kalliokoski andNiemi 2009), as well as patients on any statins with high CK levels (> 2 X 
upper limit of norm al (ULN)) at screening (Visit 1) will be excluded from the stud
y. 
Furthermore, patients on statin medication who are included in the study  will have regular 
monitoring for relevant symptoms and be subject to discontinuation based on persistent 
myalgia and blood CK levels ( Jacobson 2008).
Overall, the safet y profile of QAW039 has been favorable across studies. Three Phase [ADDRESS_834482] of QAW039 across the range of 
asthma severi ties (mild to severe). For detailed information on the studies described 
below, please refer to the I nvestigator's Brochure (IB).

[COMPANY_001] Confidential Page 24
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
[ADDRESS_834483] of approximately  93 male and female patients aged 18 and 
above, diagnosed with nasal polyposis with polyps size ≥ 4 (nasal polyp score, assessed by [CONTACT_626233] y) with a minimum score of 2 in each nostril; and a concomitant diagnosis of asthma.
5.[ADDRESS_834484] meet allof the foll owing criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2.Patients aged ≥ 18 y ears with a diagnosis of nasal poly posis with poly p size score ≥ 4 and 
a minimum score of 2 in each nostril, measured b y nasal endoscop y at screening and prior 
to randomization on Run -in/Treatment Day  1 (to ensure no reduction in NPS following the 
use of the mometasone furoate SoC therap y).
3. Patients with a concomitant diagnosis of asthma for a period of at least [ADDRESS_834485] inhaled corticosteroids (any  
dose), alone for at least 6 months prior to Screening or ICS for 6 months prior to screening 
with any  other required, inhaled asthma medication (LABA, LAMA) added at least [ADDRESS_834486] exacerbation window has passed.
2.Chronic/maintenance use of oral corticosteroids (OCS) or sy stemic corticosteroids (SCS) 
defined as an y continuous use of OCS/SCS for a period of [ADDRESS_834487] degree AV block without a pacemaker.
4.Patients with a history  of familial long QT syndrome or known famil y history of Torsades 
de Pointes.
5.Patients with a resting QTcF (Fridericia) ≥ 450 msec (males) or ≥ 460 msec (females) at 
screening.
6. Use of biologics (omalizumab, mepolizumab, reslisumab, dupi[INVESTIGATOR_12458], benralizumab etc., 
for asthma or any other indications) that has potential to interfere/affect asthma or NP 
disease progression, within 6 months of the start of the Run- in period.
7.Use of medication for sino -nasal s ymptoms (antibiotics with or without OCS) within 30 
days of Screening or du ring the Run- in period.

[COMPANY_001] Confidential Page 25
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
8.Use of tetracy cline (e.g. doxy cycline) or macrolide antibiotics specificall y within the [ADDRESS_834488] on Nasal 
Polyps.
9.Any contra -indications to inhaled or nasal stero ids e.g. narrow angle glaucoma, or an y 
other as decided b y the Investigator.
10.Pregnant or nursing (lactating) women
11.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they are using basic methods of c ontraception during dosing of 
investigational drug. Basic contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovula tion 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before taking 
investigational dru g. In case of oophorectom y alone, only when the reproductive 
status of the woman has been confirmed b y follow -up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps). For [LOCATION_006]: with spermicidal foam/gel/film/cream/ vaginal 
suppository
Use of oral, (estrogen and progesterone), injec ted or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy  
(failure rate <1%), for example hormone vaginal ring or transdermal hormone 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem 
(IUS)
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_834489] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligati on at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by
 [CONTACT_50085].
If local regulations deviate from the co ntraception methods listed above to prevent 
pregnancy , then local regulations apply  and will be described in the informed consent 
form. 
12. Use of other investigational drugs within [ADDRESS_834490] has returned to baseline, whichever is longer.
13.History  of hypersensitivity  to any  of the study  drugs or its excipi[INVESTIGATOR_201014].

[COMPANY_001] Confidential Page 26
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
14.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 y ears, regardless 
of whether there is evidence of local recurrence or metastases.
15.Patients who are unable to follow instructions to complete the study , either because of 
menta l or physical conditions.
16.Patients with a terminal disease, or conditions that may  impede the timely  completion of 
the study  as decided b y the investigator.
17.Patients with a diagnosis of Cy stic Fibrosis
18.History  of nasal surgery  (including pol ypectom y) within [ADDRESS_834491] 
scan.
22.Patients with ACQ -5 ≥ 1.5 at Screening
23.Uncontrolled epi[INVESTIGATOR_626200], including nasal 
packing, within 2 months of screening
24.Concomitant conditions that interfere with evaluation of the primary  endpoint:
Marked nasal septal deviation occluding one or both nostrils
Ongoing rhinitis medicamentosa
Acute sinusitis, nasal infection or upper respi[INVESTIGATOR_626201] -in 
period.
25.Initiation of or change in immunotherapy  or aspi[INVESTIGATOR_626202] 3 
months prior to Screening or during the Run
-in period.
26.Patients receiving an y medications in the classes listed in Table 6-2should be excluded 
unless they  meet the criteria as specified in Table 6-2.
27. Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg of pravastatin, or >[ADDRESS_834492] atin doses less than or equal to these doses 
as well as other statins will be permitted during the study
28.Patients on any  statin therapy  with a CK level >[ADDRESS_834493] which in the opi[INVESTIGATOR_457521] .
32.Patients with a history  of chronic lung disease other than asthma, including (but not 
limited to) chronic obstructive pulmonary  disease, bronchiectasis, (non -clinically  
significant bronchiectasis may  be allowed provided recent [within 3 months prior to 
Screening Visit] CT scan proof is available), sarcoidosis, interstitial lung disease, and 
tuberculosis.

[COMPANY_001] Confidential Page 27
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
33.Patients with uncontrolled diabetes having an HbA1c test result ≥8% at the Screening 
Visit laboratory  test.
34.Patients who have a clinically  significant laboratory  abnormalit y at the 
Screening laboratory  test including (but not limited to):
• Total white b lood cell count <2500 cells/µL  
• AST or ALT>2.[ADDRESS_834494] or total bilirubin >1.[ADDRESS_834495] 
• Estimated Glomerular Filtration Rate (eGFR) by [CONTACT_626234] (MDRD) equation or Bedside Schwartz equation <55 mL /minute/1.[ADDRESS_834496] a clinically  significant condition 
such as (but not limited to) unstable ischemic heart disease, NYHA Class III/IV left 
ventricular failure, arrh ythmia, uncontrolled hy pertension, cerebrovascular disease, 
neurod egenerative diseases, or other neurological disease, uncontrolled h ypo-and 
hyperthy roidism and other autoimmune diseases, hy pokalemia, hy peradrenergic state, or 
ophthalmologic disorder or patients with a medical condition that might compromise 
patient saf ety or compliance, interfere with evaluation, or preclude completion of the 
study .
36.Patients who have smoked or inhaled an y substance other than asthma medications within 
the [ADDRESS_834497] a smoking history  of greater than 
10 
pack years (Note:10 pack y ears = 1 pack /day  x 10 y rs., or ½ pack/day  x 20 y rs.).
37.Patients with a history  of my ocardial infarction within 12 months of Screening.
38. Patients with serious co- morbidities including, but not limited to, neurodegenerative 
disea ses, rheumatoid arthritis and other autoimmune diseases.
39.Patients with a history  of alcohol or drug abuse within 12 months prior to Screening.
40.Patients with a weight <[ADDRESS_834498].
46.No family  member of the investigational study  staff is allowed to participate in this study .
47.History  of lactose or milk sensitivity .
48.Patients with a history  of conditions other than asthma that could result in elevated 
eosinophils (e.g., h ypereosinophilic sy ndromes, Churg- Strauss Sy ndrome, eosinophilic 
esophagitis). Patients with known parasitic infestation within 6 m onths prior to Screening 
are also excluded.
49. Patients requiring SCS use for conditions other than asthma (chronic or intermittent) or 
nasal polyposis.
No additional exclusions may be applied by [CONTACT_737], in order to ensure that the study 
population will be representative of all eligible subjects

[COMPANY_001] Confidential Page 28
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
6 Treatment
6.1 Stud y treatment
6.1.1 Investigational and control drugs
The following investigational treatment will be supplied by  [CONTACT_540335]:
Name: [CONTACT_626275][INVESTIGATOR_105169] (labeled as QAW039)
Formulation: tablet
Unit dose: 2 strengths: 150 mg and 450 mg
Please refer to the Investigator’s Brochure for composition of the fevipi[INVESTIGATOR_591163].
Name: [CONTACT_626275][INVESTIGATOR_626203]
Formulation: tablet
Unit dose: matching placebo to fevipi[INVESTIGATOR_105169] 150 mg, matching placebo to fevipi[INVESTIGATOR_626204] 450 
mg
Please refer to the Investigator’s Brochure for composition of the placebo tablets.
The investigational treatment (tablets) will be supplied in bottles. The matching placebos for 
fevipi[INVESTIGATOR_626205].
6.1.2 Additional study treatments
At the start of the Run-in period, all patients will be provided with mometasone furoate 
nasal spray  (no specific brand required) as the SoC for use during the stud y. This will either be 
supplied to the Investigator sites by [CONTACT_626235]. 
All patients will remain on their current asthma treatment for the duration of the study  (with the 
exception of LTRAs, which should be discontinued prior to patients entering the Run-in period). 
Patients will also be provided with short -acting β2-agonists (SABAs), 
(salbutamol/albuterol/other SABA) which they will be instructed to use throughout the study  as 
rescue medication to treat asthma symptoms on an ‘as needed basis’. SABAs will either be 
supplied to the I nvestigator sites by  [CONTACT_626236].
Should patients develop any sino-nasal exacerbations during the course of the study , the treating 
physician should follow their norm al treatment regimen with systemic corticosteroids and/or 
antibiotics.
6.1.3 Treatment arms/group
Subjects will be assigned at the randomization visit to one of the following 3 treatment arms in 
a ratio of 1:1:1.
During the Run-in period, all patients will recei ve the NPSoC treatment only -Mometasone 
Furoate 200 µg once daily , administered as two 50 µg actuations into each nostril.
For the treatment period, patients will be assigned to one of three treatment arms as follows in 
a 1:1:1 ratio:

[COMPANY_001] Confidential Page 29
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
QAW039 150 mg once daily  (one tablet of blinded QAW039 at 150 mg dosage strength to 
be given together with one tablet blinded placebo to QAW039 450 mg).
QAW039 450 mg once daily  (one tablet of blinded QAW039 at 450 mg dosage strength to 
be given together with one tablet blin ded placebo to QAW039 150 mg).
Placebo to QAW039 once daily  (one tablet blinded placebo to QAW039 150 mg and one 
tablet blinded placebo to QAW039 450 mg).
Patients will be instructed to take their investigational treatment (QAW039 or placebo) once 
daily  in the morning without regard to time of food intake.
6.1.4 Treatment duration
The planned duration of the study  treatment period is 16 weeks from the point of randomization. 
Subjects will take their assigned study  treatments along with the NP SoC which will be supplied 
to patients at the start of the Run-in period. The patients will administer the SoC only, during 
the Run-in period and then administer both the SoC and the study  treatment, during the 16-week 
Treatment period.
6.2 Other treatment(s)
All patients will be provided with short -acting β2-agonists (SABAs) 
(salbutamol/albuterol/other SABA) which they will be instructed to use throughout the study  as 
rescue medication on an ‘as needed basis.’
6.2.1 Concomitant therapy
All medications, procedures and significant non -drug therapi[INVESTIGATOR_014] (including physical therap y and  
blood transfusions) administered after the subject was enrolled into the study must be recorded 
on the appropriate Case Report Forms (CRFs). The medications in Table 6-1are only permitted 
under the circumstances given and this table is not considered all -inclusive.
Each concomitant drug must be individually  assessed for adherence to the indication and against 
all exclusion criteria/prohibited medication. If in doubt the Investigato r should contact [CONTACT_626237]/sponsor medical monitor before randomizing a subject or allowing a new medication 
to be started. If the subject is alread y enrolled, contact [CONTACT_5343]/sponsor to determine if the 
subject should continue participation in the stu dy.
Table [ADDRESS_834499] (SABA) Rescue medication to be taken as needed
SCS for treatment of symptoms of asthma or NP One treatment of up to [ADDRESS_834500] 3 months prior to Screening and 
the dose remains stable throughout the study
Inactivated influenza vaccine, pneumococcal 
vaccine or any other inactivated vaccineNot administered with 48 hour prior to a study visit
Topi[INVESTIGATOR_626206] 30
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Class of medication Conditions
Antihistamines (e.g. loratadine, cetirizine) Stable for at least [ADDRESS_834501] the [COMPANY_001] medical 
monitor or designee before randomizing a patient or allowing a new medication to be started. 
This table is not considered all -inclusive. Medications should be assessed for adherence to the 
indication and other inclusion/exc lusion criteria. These medications are also prohibited if 
administered for other indications.
Table 6-2 Prohibited Medication
Medication Prohibition period (Minimum cessation prior to Run -in)
Other investigational drugs 30 days or 5 half -lives, whichever is longer
Oral and Nasal Decongestants (more than 3 weeks 
total use)30 days
Live attenuated vaccine 30 days
Simvastatin > 20 mg, atorvastatin > 40 mg, 
pravastatin > 40 mg, or pi[INVESTIGATOR_2830] > 2 mg total 
daily dose7 days
Other DP2 antagonists (e.g., ramatroban) [ADDRESS_834502] cell stabilizers (e.g.,cromoglycate, 
nedocromil, ketotifen)7 days
Monoclonal antibodies, investigational or approved, 
for the treatment of asthma (e.g., omalizumab)6 months
Nasal corticosteroids in the form of d rops, sprays 
that are administered via devices (e.g. OptiNose 
device or stents) or lavage8 weeks
Tetracyclic or macrolide antibiotics 8 weeks
Rifampin, probenecid, ritonavir and valproic acid 
(i.e. medications blocking several pathways 
important for the elimination of QAW 039 (broad 
range UGT inhibition and/or inhibition of OAT3, 
OATP1B3, MXR and P-gp)).7 days
Methotrexate, gold salts, cyclosporine, 
troleandomycin, azathioprine, other immuno -
modulator drugs or immuno -modulatory monoclonal 
antibodies6 months
Systemic (oral, intravenous, intramuscular) 
corticosteroids for non -asthma conditions3 months

[COMPANY_001] Confidential Page 31
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
Medication Prohibition period (Minimum cessation prior to Run -in)
Leukotriene receptor antagonists (LTRA) Stopped at beginning of Run -in period
6.2.3 Rescue medication
At the start of the Run-in period, all patients will be provided with a SABA (such as salbutamol 
100 mcg or albuterol 90 mcg) which they will be instructed to use throughout the study  as rescue 
medication on an ‘as needed basis’. Patients will be advised that between visits they could take 
their rescue medicati on for symptoms of asthma. Rescue medication (i.e., SABAs) will either 
be supplied to the Investigator sites locally  by [CONTACT_626238] (CPO) 
or sourced locall y and reimbursed by [CONTACT_5343]. Nebulized salbutamol/albuterol is not allowed 
as rescue medication and will not be supplied.
Should patients develop any sino-nasal exacerbations during the course of the study , the treating 
physician should follow their normal treatment regimen with systemic corticosteroids and/or 
antibiotics. Short term oral or nasal decongestants may also be utilised as a rescue therapy 
however the assessment of NPS must not be performed within [ADDRESS_834503] Number (Subject No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary identifier for the subject 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential subject 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the patient is assigned to the next sequential Subject 
No. available.
6.3.2 Treatment assignment, randomization
At randomization visit, all 
eligible subjects will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The Investigator or his/her delegate will contact 
[CONTACT_286774]/exclusion criteria. The IRT 
will assign a randomization number to the pati ent, which will be used to link the patient to a 
treatment arm and will specify  unique medication numbers for the first packages of study  drug 
to be dispensed to the patient. The randomization number will not be communicated to the caller.
The randomizatio n numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and Investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated system that automates 
the random assignment of patient numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medication list will be produced by [INVESTIGATOR_82896] r esponsibility  of [COMPANY_001] 
Global Clinical Supplies using a validated system that automates the random assignment of 
medication numbers to packs containing the investigational drug(s).

[COMPANY_001] Confidential Page 32
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
The randomization scheme for subjects will be reviewed and approved by [CONTACT_626239].
6.4 Treatment blinding
Subjects, Investigator staff, persons performing the assessments, and clinical trial team (CTT) 
will remain blind to the identity of the treatment from the time of randomization until database 
lock, using the following methods: (1) Randomization data are kept strictly confidential until 
the time of unblinding, and will not be accessible by  [CONTACT_121927] , (2) the 
identity  of the treatments will be concealed by [CONTACT_626240], labeling, schedule of administration, appearance, taste and odor.
A double -dummy  design is used because the identity  of the study  treatment cannot be disguised, 
as the drug products are visibly  different.
Unblinding will occur in the case of subject emergencies and at the conclusion of the study .
Table 6-[ADDRESS_834504] 
generatedTreatment allocation 
& dosingSafety  event (single 
subject unblinded)
Subjects B B B
Site staff B B B
Unblinded site staff e.g. pharmacy 
staff (specify)B B B
Drug Supply and Randomization 
OfficeUI UI UI
Unblinded Pharmacovigilance 
sponsor staffUI UI UI
Statistician/statistical programmer/ 
data analysts (e.g. biomarker, PK)B B B
Independent committees used for 
assessing interim results, if 
required (e.g. DMC)NA NA NA
All other sponsor staff not 
identified above (trial team, project 
team, management & decision 
boards, support functions)B B B
Key:
UI: Allowed to be unblinded on individual subject level
B: Remains blinded
NA: Not applicable to this study
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions are not permitted 
and should an y such changes in dosing regimen occur during the stud y then the patients will be 
excluded unless highlighted as a rescue therap y within other sections of the protocol.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
6.5.1 Dose modifications
For subjects who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are not permitted and the patients will be withdrawn from the study . 
6.5.[ADDRESS_834505]'s safet y and the 
validity  of the stud y. The subject must also be instructed to contact [CONTACT_18611]/she is 
unable, for an y reason, to take the study treatment as prescribed.
Compliance will be assessed by  [CONTACT_11219]/or study  personnel at each visit using pi[INVESTIGATOR_626207]. This information should be captured in the 
source document at each visit. All study  treatment dispensed and returned must be recorded in 
the Drug Accountability  Log.
All doses of study  drug taken at the clinic visits must be from the newl y assigne d medication 
bottles, except at the end of treatment (EOT) visit when the medication returned by [CONTACT_626241].
6.6.[ADDRESS_834506], he/she must provide 
the requested subject identify ing information and confirm the necessity  to break the treatment 
code for the subject. The Investigator will then receive details of the investigational drug 
treatment for the specified subject and a fax or email confirming this information. The sy stem 
will automatically  inform the [COMPANY_001] monitor for the site and the study  team that the code has 
been broken.
It is the Investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The Investigator 
will provide:
protocol number
name
subject number
In addition, oral and written information to the subject must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency , or when he/she is unavailable, to ensure that unblinding 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
can be performed at an y time. Following an y emergency breaking of the blind, the subject wi ll 
be withdrawn from the study .
6.[ADDRESS_834507] by [CONTACT_37246](s). The study medication has a 2 -part label (base 
plus tear-off label), immediately  before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source 
document.
6.7.1 Handling of study treatment and additional treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and prope rly, and kept in a secured location to which only  the Investigator and designees 
have access. Upon receipt, all study  treatment must be stored according to the instructions 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol. Technical complaints are to be reported to the respective [COMPANY_001] CPO Qualit y 
Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the patient except for the medication number.
The Investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed b y 
monitors during site visits or remotely  and at the completion of the trial. Patients/subjects will 
be asked to return all unused study  treatment and packaging at the end of the study  or at the 
time of discontinuation of study  treatment.
Atthe conclusion of the study , and as appropriate during the course of the study , the Investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the Investigator 
folder at each site.
[IP_ADDRESS] Handling of additional treatment
The following non -study  treatment has to be monitored specificall y:
Mometasone furoate 200 µg used as SoC
SABA (such as salbutamol 100 µg)
The non-investigational treatment must be received by a  designated person at the study  site, 
handled and stored safely  and properl y, and kept in a secured location to which only the 
Investigator and designees have access. Clinical supplies are to be dispensed only in accordance 
with the protocol.

[COMPANY_001] Confidential Page 35
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
The Investigator must maintain an accurate record of the shipment and dispensing of the non-
investigational treatment in a drug accountability log. Monitoring of drug accountability  will 
be performed by [CONTACT_626242]. 
Patients will be asked to return all unused non- study  treatments and packaging at the end of the 
study  or at the time of discontinuation from the study .
6.7.2 Instruction for prescribing and taking study treatment
Study  treatment will be double -blind, double -dummy , and placebo -controlled during the 
treatment period. QAW039 will be supplied as tablets. Since the tablets for QAW039 150 mg 
and QAW039 450 mg are not identical, treatment will be double -dummy  and patients will ta ke 
2 tablets of study  medication (one tablet of blinded QAW039 at 150 mg dosage strength to be 
given together with one tablet blinded placebo to QAW039 450 mg or one tablet of blinded 
QAW039 at 450 mg dosage strength to be given together with one tablet blinded placebo to 
QAW039 150 mg or one tablet blinded placebo to QAW039 150 mg and one tablet blinded 
placebo to QAW039 450 mg) once dail y as described below.
During the Run-in period, all patients will start treatment with mometasone furoate [ADDRESS_834508] passed after full 
recovery  from the exacerbation.
At the Randomization Visit (Treatment Day 1) patients will be randomized to receive one of 
the three stud y treatments:
QAW039 150 mg once daily
QAW039 450 mg once daily
placebo once dail y
The treatment period will continue for a period of 16-weeks and patients will continue to take 
the mometasone furoate SoC in addition to the study  treatments, during the treatment period. 
The investigational treatment will be dispensed in medication packs (bottles) at each clinic visit 
during the treatment epoch with enough medication supplied to cover the period between patient 
visits and to allow for late visits and other unforeseen events. 
All dosages prescribed and 
dispensed to the p atient must be recorded in the appropriate section of the CRF.
At clinic visits, patients will receive a witnessed dose of study  medication. These in-clinic 
witnessed doses will be given after the completion of all pre-dose assessments (see Section 8) 
and should be given at approximately  the same time at each clinic visit. Between clinic visits, 
patients will take study  medication once daily in the morning. Patients will be instructed to take 
their study  medication at approxima tely the same time each morning.
All kits of study  treatment assigned by  [CONTACT_157085].
The Investigator must promote compliance by [CONTACT_18610]’s safet y and the 
validity  of the study . The patient must also be instructed to contact [CONTACT_18611]/she is 
unable for an y reason to take the stud
y treatment as prescribed .

[COMPANY_001] Confidential Page 36
Amended Protocol Version 03 (Clean ) Protocol No. CQAW 039A2322
7 Informed consent procedures
Eligibl e patients/subjects may  only  be included in the study  after providing signed (witnessed, 
where required by [CONTACT_6617]), IRB/ IEC-approved informed consent, or, if applicable 
after such consent has been provided by a legall y acceptable representative( s) of the patient. In 
cases where the patient’s representative gives consent, the patient must be informed about the 
study  to the extent possible given his/her understanding. If the patient is capable of doing so, 
he/she must indicate assent by  [CONTACT_37249] y signing and dating the informed consent document or 
a separate assent form. Informed consent must be obtained before conducting any study -specific 
procedures (e.g. all of the procedures described in the protocol). The process of obtaining 
informed consent must be documented in the patient source documents.
[COMPANY_001] will provide to Investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory  requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_317633]/ IEC, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC approval.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirement for the duration of 
the study . If there is any question that the patient will not reliably  compl y, they must not be 
entered in the stud y.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Broc hure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. Any new 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an Investigator notification or 
an aggregate safet y finding. New information might require an update to the informed consent 
and then must be discussed with the subject.
Subjects might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.
8 Visit schedule and assessments
Assessment schedule lists all of the assessments and indicates with an “X” or an "S", the visits 
when they are performed. All data obtained from 
these assessments must be supported in the 
patient’s source documentation with those events marked by [CONTACT_1629] "X" being captured in the 
CRF/Clinical Database and those marked with an "S" will be captured in source documentation 
only.
Patients should be seen for all visits/assessments as outlined in the assessment schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontinuation. Patients who prematurely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adverse event and co ncomitant medications recorded on the CRF.

[COMPANY_001] Confidential Page 37
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Table 8-1 Assessment Schedule
Period Screening Treatment
Visit Name [CONTACT_222003]-in1TreatmentEOT or 
TDFollow -up
Days -42 to -28 -28 to -1 1 1 28 56 84 112 124
Weeks -6 to -4 -4 to -1 1 1 4 8 12 16 18
Informed consent X
Inclusion / Exclusion criteria X X X
Demography X
Physical Examination S S
Medical history/current medical 
conditionsX
Surgeries and Procedures X
Prior medications X
Safety Follow up Call S
ACQ -5 X
Vital Signs X X X X X X X
Body Height X
Electrocardiogram (ECG) X X X
Body W eight X
Pregnancy Test (serum) X
Pregnancy Test (Urine) S S S S S
Hematology X X X X
HbA1C X X
Clinical Chemistry X X X X
Urinalysis X X
Check IMP Compliance S S S S
Contact [CONTACT_12067] (IVRS/IW RS) S S S S S S S S
Randomization S

[COMPANY_001] Confidential Page 38
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Period Screening Treatment
Visit Name [CONTACT_222003]-in1TreatmentEOT or 
TDFollow -up
Days -42 to -28 -28 to -1 1 1 28 56 84 112 124
Weeks -6 to -4 -4 to -1 1 1 4 8 12 16 18
Study Drug Dispensation S S S S
Study drug administration Daily
SoC/Rescue Medication Dispense S S S S S S
Adverse Events X X X X X X X X
Serious Adverse Events X X X X X X X X
Concomitant medications X X X X X X X X
Liver Event Monitoring2X X X X X X X X X
Renal Event Monitoring3X X X X X X X X X
Nasal Endoscopy4X X X X
Nasal Congestion Score 
QuestionnaireX X X X X X X
QoL Questionnaire (SNOT-22) X X X X X X X
Smell Assessment (UPSIT) X X X X X X X
Study completion information X
XAssessment to be recorded in the clinical database or received electronically from a vendor
SAssessment to be recorded in the source documentation only
1Assessments at Run-in Day [ADDRESS_834509] on the same day if the patient is 
randomized
2Please refer to pr otocol Section 10.2.1
3Please refer to protocol Section 10.2.2
4Nasal polyp score will be determined by [CONTACT_18014]. 
5 
6For patient familiarization with device only. 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
8.1 Screening
Patients will be scheduled to attend for the screening visit within 14 days of the scheduled start 
of the Run -in period. It is permissible to re -screen a patient if he/she fails the initial screening; 
however, each case must be discussed and agreed with No vartis on a case -by-case basis.
8.1.1 Information to be collected on screening failures
Subjects who signed an informed consent form and subsequently  found to be ineligible prior to 
randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate Case Report Form. The demographic information, informed 
consent, and Inclusion/Exclusion pages must also be completed for screen failure subjects. No 
other data will be entered into the clinical database for subjects who are screen failures, unless 
the subject experienced a serious adverse event during the screening phase (see SAE Reporting 
Section, Section 10.1.3 for reporting details). If the subject fails to be randomized, the IRT must 
be notified within [ADDRESS_834510] demographics/other baseline characteristics
Patient demographic and baseline characteristic data to be collected on all patients include:
Date of birth (where allowed by  [CONTACT_19666])
Age (ca lculated)
Sex
Race and ethnicity
Patients initials (where allowed by  [CONTACT_19666])
Height and Weight
BMI (calculated)
Baseline ph ysical examination (not databased other than in the context of relevant medical 
history )
Vital signs
Date of diagnosis of asthma
Relevant medical history/ current medical condition present before signing the informed 
consent
Asthma Control (ACQ-5)
Prior concomitant medication (Both asthma/NP related and non -asthma/NP related)
8.3 Efficacy
The following assessments of efficacy  will be performed:
Nasal Poly p Score
Patient- reported Outcomes (NCS and SNOT -22)

[COMPANY_001] Confidential Page 40
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Smell (UPSIT)
8.3.1 Nasal Poly p Score
The nasal polyp score is assessed four times during the study  by [CONTACT_626222] . The initial 
assessment will be performed at screening to assess the patient ’s eligibility  on the study . 
Patients will be deemed eligible with a NPS ≥ [ADDRESS_834511] 2 in one nostril, 
determined by [CONTACT_626243], using the following scale 
(Gevaert et al 2013):
Table [ADDRESS_834512] be received for the baseline 
assessment, prior to randomization. At the 8and 16-week treatment visits, NPS will again be 
re-assessed for efficacy . The readings from the endoscopi[INVESTIGATOR_626208].
The nasal endoscopy  may be performed on a different day from the other study procedures as 
long as this is performed within 
approximately  5 day s of the original scheduled visit.
Note that the nasal endoscopy  procedure should not be performed within 3 days of any 
concomitant use of oral or nasal decongestants.
8.3.2 Patient Reported Out comes
A patient reported outcome (PRO) is an y report of the status of a patient’s health condition that 
comes directl y from the patient, without interpretation of the patient’s response by a clinician 
or anyone else. Patient reported outcomes may provide quantitative information for patients 
regarding the ‘impact on daily  life’, which is of key importance, for patients and their physicians 
and also for health technology  assessments. In this study , 
two PROs are used to assess the 
improvement in symptoms (nasal congestion score) and quality  of life (SNOT -22). All PROs 
should be completed prior to any other assessments (especially  the nasal endoscop y) to avoid 
any influence on the responses.
[IP_ADDRESS] Symptoms (Nasal Congestion Score)
The nasal congestion score is asse ssed via a questionnaire where the patients are asked "Is your 
nose blocked?" with responses ranging from 0 = not at all, to 3=severe. The test is performed 
within the clinic at the visits outlined in Table 8-1on a tablet comp uter and the questionnaire is 
outlined in Section 16.4.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
[IP_ADDRESS] Quality  of Life (SNOT -22)
For this study , the SNOT -22 questionnaire (listed in Section 16.5) will be used to assess any 
improvement in the patients quality  of life. The questionnaire consists of 22 questions relating 
to various quality  of life indicators and answers 
are scored from 0 (no problem) to 5 (problem 
as bad as it can be) with questions relating to the patients experience in the previous [ADDRESS_834513] will be self-administered by [CONTACT_626244] a tablet computer at the clinic visits outlined 
in Table 8-1and takes only  a few minutes to complete. The final outcome is a total score from 
0 to 110.
8.3.3 Smell (UPSIT)
For this study , any change in the patients sense of smell will be assessed using the Universit y 
of Pennsylvania Smell I dentification Test. The test comprises of a kit which will be supplied to 
sites. The test includes 4 workbooks, each of which contains 10 microencapsulated (scratch and 
sniff) odors with forced choice responses accompany ing each test item. The sites will also be 
supplied with the relevant instruction manual and scoring key .
The test is administered at the clinic visits and usually  takes 10-15 minutes to complete. The 
result is a score out of 40 and this will be captured within the Clinical Database by [CONTACT_89184].
8.3.4 Appropriateness of efficacy  assessments
The efficacy  assessments outlined above are deemed to be sufficien t for the objectives of the 
study .
8.4 Safet y
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to AE section.
Table 8
-3 Physical A ssessments
Assessment Specification
Physical 
examinationA complete physical examination will include the examination of general appearance, 
skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular, and neurological. If indicated based on medical 
history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be 
performed.
Information for all physic al examinations must be included in the source documentation at 
the study site. Clinically relevant findings that are present prior to signing informed 
consent must be recorded on the appropriate CRF that captures medical history. 
Significant findings made after first administration of investigational drug which meet the 
definition of an Adverse Event must be recorded as an adverse event.

[COMPANY_001] Confidential Page 42
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Assessment Specification
Vital signs Vital signs include blood pressure and pulse measurements. After the subject has been 
sitting for five minu tes, with back supported and both feet placed on the floor, systolic and 
diastolic blood pressure will be measured three times using an automated validated 
device, e.g. OMRON, with an appropriately sized cuff. The repeat sitting measurements 
will be made a t [ADDRESS_834514]'s arm 
circumference, a sphygmomanometer with an appropriately sized cuff may be used.
Height and 
weightHeight in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured.
8.4.[ADDRESS_834515] Name
[CONTACT_157131], Hemoglobin, MCH, MCHC, MCV, Platelets, Red blood cells, W hite blood 
cells, Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, 
Other).
Clinical Chemistry Albumin, Alkaline phosphatase, ALT , AST , Gamma -glutam yl-transferase (GGT),
Lactate dehydrogenase (LDH), Calcium, Magnesium, Phosphorus, Chloride ,Sodium, 
Potassium, Creatinine, Creatine kinase, CK -MB and Troponin I (in response to CK 
results outside of the normal range), HbA1c (collected at Screening visit a nd EOT 
only), Direct Bilirubin, Total Bilirubin, Total Cholesterol, Total Protein, Triglycerides, 
Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose.
Urinaly sis Microscopic Panel (Red Blood Cells, W hite Blood Cells, Casts, Crystals, Ba cteria, 
Epi[INVESTIGATOR_1663]) -if required.
Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes 
esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)
Urine chemistry and microscopic examination of the urine will be p erformed by [CONTACT_626245] 10.2.2 "Renal Safety Monitoring" 
andSection 16.3 "Specific Renal Alert Criteria and Actions and Event Follow -up"
Coagulation International normalized ratio (INR), activated partial thromboplastin time (APTT)
Pregnancy  Test Serum / Urine pregnancy test
8.4.2 Electrocardiogram (ECG)
ECGs will be measured according to the assessment schedule in Table 8-1. ECGs must be 
recorded after [ADDRESS_834516], followed 
by [CONTACT_18651]. The Fridericia QT correction form ula (QTcF) should be used for clinical 
decisions.
Single 12-lead ECGs will be collected using the sites own ECG machines and key parameters 
and the original trace available within the source data.

[COMPANY_001] Confidential Page 43
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
For any ECGs with subject safet y concerns, two additional ECGs must be performed to confirm 
the safet y finding. A monitoring or review process should be in place for clinically  significant 
ECG findings throughout the study  and especially  at baseline before administration of study  
treatment. Clinically  significant abnormalities must be recorded on the CRF as either medical 
history /current medical conditions or adverse events as appropriate.
Any identifier details must be redacted e.g subject initials, date of birth.
8.4.[ADDRESS_834517] serum/urine pregnancy 
testing. Additional pregnancy  testing might be performed if requested by  [CONTACT_5277].
8.4.[ADDRESS_834518] for this indication/patient po pulation.
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
COAs are utilised on this study  for assessment of study  eligibility  and also as part of the 
secondary  study objectives. Those COAs related to the study  objectives and efficacy  are 
documen
ted in protocol Section 8.3.2.
The remaining COAs used on this study  are documented as follows.
[IP_ADDRESS] Asthma Control Questionnaire (A CQ-5)
In this study  the ACQ -5 will be used as Exclusion criterion at screening in order to identify 
those 
subjects who are currentl y symptomatic and who may exacerbate during the Run-in or 
treatment periods.
The ACQ -5 will be self -administered at the clinic during the screening visit and it onl y takes a 
few minutes to complete. Patients will be asked to recall how their asthma has been during the 
previous week and to respond to the sy mptom questions on a 7 -point scale (0=no impairment, 
6=maximum impairment). The questions are equally  weighted and the ACQ -5 score is the mean 
of the 5 questions and therefore between 0 (totally  controlled) and 6 (severel y uncontrolled) 
(Juniper et al 1999; Juniper et al 2005) ( Section 16.6).

[COMPANY_001] Confidential Page 44
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
[ADDRESS_834519] discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would negativel y impact the risk/benefit of trial participatio n.
Study  treatment must be discontinued under the following circumstances:
Withdrawal of informed consent (and the Investigator must prematurel y withdraw the 
patient from the study );
Pregnancy ;
Female subjects non -compliant with the chosen effective method of contraception during 
the study : The Investigator must provide appropriate advice on the continued use of 
effective contraception for at least one week (at least 5 half-lives of QAW039) after stud y 
drug discontinuation and follow up with the subject as appropriate at least to the end of 
this period;
Any protocol deviation that results in a significant risk to the patient’s safety ;
Liver laboratory  test abnormality  / event (see Section 16.2 ): 
Abnormal liver laboratory  results requiring discontinuation – refer 
to Table 16-1 -Section 16.2 ;
If the Investigator considers it appropriate after the confirmation of a liver safet y 
monitoring signal: 

[COMPANY_001] Confidential Page 45
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
ALT or AST ≥ [ADDRESS_834520], or
ALT or AST ≥ 2.5xUL N andtotal bilirubin (TBL) ≥ 1.5xUL N ( Section 16.2 );
Any laboratory  abnormalities that in the judgment of the Investigator, taking into 
consideration the subject’s overall status, prevents the subject from continuing 
participation in the study;
Premature unblinding of study  treatment for a patient for an y reason; please refer 
to Section 6.6.2 ;
Total white blood cell count < 1000 cells/µL ;
Patient requires SCS/OCS use for a period of more than 5 consecutive day s during the 
study . Any OCS/SCS use in addition to this allowed 5 days of treatment will result in 
withdrawal;
If patients on statin therapy  complain of persistent muscle pain without any obvious cause
for greater than 3 day s, accompanied b y an increase in CK levels >10xULN or persistent 
intolerable muscle pain, regardless of the accompany ing CK level;
If a patient undergoes nasal surgery , including but not limited to the following: treatment 
of nasal pol yposis, septal deviation correction, turbinectomy, para -nasal sinus drainage, 
nasal plastic surgery , hypophy sis tumor nasal approach.
If a patient develops a medical condition, that requires consistent use of prohibited 
treatment as per Section 6.2.[ADDRESS_834521]’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see withdraw of informed consent section,). Where possible, they should return 
for the assessments indicated in the Assessment schedule ( Table 8-1).
After study  treatment 
discontinuation, at a minimum, in abbreviated visits, the following data 
should to be collected at clinic visits or via telephone visits:
new/concomitant treatments including OCS use
adverse events/Serious Adverse Events
If they  fail to return for these assessments for unknown reasons, ever y effort (e.g. telephone, e -
mail or letter) should be made to contact [CONTACT_423]/pre -designated contact [CONTACT_626246] -up section. This contact [CONTACT_37283] y be done according to the study  visit 
schedule.
If the patient cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact [CONTACT_10970], or with a person pre-designated by [CONTACT_102]. This telephone 
contact [CONTACT_626247]. The information 
alread y collected during the study  including your samples will still be used according to 
applicable laws

[COMPANY_001] Confidential Page 46
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
The Investigator must also contact [CONTACT_105253]’s discontinuation from study 
treatment.
9.1.[ADDRESS_834522]:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the Investigator should make a reasonable effort (e.g. telephone, e-mail or letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_5366] -
up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
For US: All biological samples not yet analyzed at the time of withdrawal may still be used for 
further testing/anal ysis in accor dance with the terms of this protocol and of the informed consent 
form.
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  [CONTACT_1289]. They will be stored according to applicabl e 
legal requirements.
9.1.[ADDRESS_834523] show "due diligence" by 
[CONTACT_762], e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  [CONTACT_626248]. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
[COMPANY_001] will alway s consider the patient welfare and safet y. Should early  termination be 
necessary , patients must be seen as soon as possible (provide instruction for contact[CONTACT_626249] 47
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
patient, when the patient should stop taking drug, when the patient should come for a final visit) 
and treated as a prematurely  withdrawn patient. The Investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protectio n of the patient’s interests. The Investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
9.[ADDRESS_834524] visit planned in the protocol. Study  completion for a patient will occur after he/she has 
completed 16-weeks of treatment (through the follow - up visit) or they have prematurel y 
withdrawn. Completion of the study  will be when all randomized patients have completed [ADDRESS_834525] been screened when enrolment target has been met will be allowed to proceed 
onto study  participation.
For all patients a safet y follow -up visit should be conducted (e.g. by [CONTACT_756]) [ADDRESS_834526] visit (Week 16). The information to be collected at this follow up visit includes adverse 
events, concomitant medications and SAEs.
When the patient has completed all scheduled study  assessments or prematurely  withdrawn 
from the study , the Investigator must contact [CONTACT_626250] 
/discontinuation and complete applicable eCRF .
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign (including abnormal laboratory  findings), sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The Investigator has the responsibility  for managing the safet y of individual subject and 
identify ing adverse events.
[COMPANY_001] qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105] -directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.

[COMPANY_001] Confidential Page 48
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Adverse events must be recorded under the signs, symptoms or diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to 
Section 10.1.2):
1.the severit y grade
mild: usually  transien t in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.its relationship to the study
 treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘not suspected’. The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are n ot caused by  [CONTACT_6645], they  
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a 
single subject.
3. its duration (start and end da tes) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.action taken regarding with study  treatment
6.its outcome i.e., its recovery  status or whether it was fatal
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug interrupted/withdrawn
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 14 days (or 5 half-lives or end of 
study  visit, whichever is longer) following the last dose of study  treatment
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator Brochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or symptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant change s from 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_37206]. Alert ranges for laboratory and other test abnormalities are included in 
Section 16.1.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
resul ts in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
1.routine treatment or monitoring of the studie d indication, not associated with any  
deterioration in condition under study
 
2.elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
3.social reas ons and respi[INVESTIGATOR_108999]’s general 
condition
4.treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situation s should 
be considered serious reactions, such as important medical events that might not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_626209]. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guidelines).
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.

[COMPANY_001] Confidential Page 50
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
10.1.[ADDRESS_834527] be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a Chief Medical Office and 
Patient Safety  Department associate may urgently  require further information from the 
Investigator for health authority  reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all Investigators involved in any study with the same study  treatment 
that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_834528] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to deter mine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_626251] y. Pregnancy  follow -up should be recorded on the same form and should 
include an assessment of the possible relationship to the study  treatment any pregnancy  outcome. 
Any SAE experienced during pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professiona l, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error ty pe Document in Dose 
Administration Record 
(DAR) eCRF (Yes/No)Document in AE eCRF Complete SAE form
Unintentional study 
treatment errorYes Only if associated with an 
AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes Yes, even if not associated 
with a SAE
For more information on AE and SAE definition and reporting requirements, please see the, 
respective sections.
10.[ADDRESS_834529] safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evalua tion of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will requ ire repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and contributing 
factors are recorded on the appropriate CRFs
Please refer to Table 16-1-Appendix [ADDRESS_834530] (LFT) to confirm elevation.
Thes e liver chemistry  repeats will be performed using the central laboratory. If results will 
not be available from the central laboratory , then the repeats can also be performed at a 
local laboratory  to monitor the safet
y of the subject. If a liver event is s ubsequently  
reported, an y local liver chemistry tests previously conducted that are associated with this 
event should have results recorded on the appropriate CRF.
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate.

[COMPANY_001] Confidential Page 52
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Discontinuation of the investigational drug (refer to the Discontinuation of study  treatment 
section), if appropriate
Hospi[INVESTIGATOR_131539]
Causality  assessment of the liver event
Thorough follow -up of the liver event should include
These investigations can include based on Investigator’s discretion: serology tests, 
imaging and pathology  assessments, hepatologist’s consultancy ; obtaining more detailed 
history  of symptoms and prior or concurrent diseases, history  of concomitant drug use, 
exclusion of underly ing liver disease
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF
10.2.[ADDRESS_834531] to be considered during 
the course of the study :
Serum event:
Confirmed (after ≥24 hours) increase in serum creatinine (sCr) of ≥25% compared to 
baseline during normal hydration status
Urine event:
Albumin -creatinine ratio (ACR) ≥1g/g or ≥100 mg/mmol.
Protein- creatinine ratio (PCR ) ≥1g/g or ≥100 mg/mmol.
Every  renal laboratory trigger or renal event as defined in Table 16-3 -Appendix 3 should be 
followed up by [CONTACT_626252] 16 .
11 Data Collection and Database management
11.1 Data collection
Designated Investigator staff will enter the data required by [CONTACT_356105] c 
Case Report Forms using fully  validated software that conforms to US CFR 21 Part 11 
requirements. Investigator site staff will not be given access to the electronic data capture (EDC) 
system until they have been trained. Automatic validation programs check for data 
discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_113562]. The Investigator/designee is responsible for assuring that the data entered 
into the eCRF is complete, accurate and that entry  andupdates are performed in a timely  manner. 
The Investigator must certify  that the data entered is complete and accurate.
After final database lock, the Investigator will receive copi[INVESTIGATOR_37210].
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.

[COMPANY_001] Confidential Page 53
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
11.[ADDRESS_834532], which employ s the Anatomical Therapeutic Chemical classificat ion 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Randomization codes and data about all study  treatment(s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] at specific timelines.
Each occurrence of a code bre ak via I RT will be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001] .
Laboratory  samples will be processed by a central lab and the results will be provided 
elect ronically  to [COMPANY_001].
The PROs will be recorded on site by [CONTACT_626253]. The videos of the nasal endoscopi[INVESTIGATOR_626210] (either b y upload to a cloud server or postage of encrypted USB drives) 
for central reading. Videos will be read by  [CONTACT_626254] a third adjudicating reader making the decision on NPS should the original two 
readers not agree d uring their assessment.
 
 
 
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatm ent codes will be unblinded and made 
available for data analy sis.Any changes to the database after that time can only be made after 
written agreement b y [COMPANY_001] development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an Investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eCRFs) with the 
Investigators and their staff. During the study , [COMPANY_001] employ s several methods of ensuring 
protocol and GCP complianc e and the quality/integrit y of the sites’ data. The field monitor will 
visit the site to check the completeness of subject records, the accuracy  of data capture / data 
entry , the adherence to the protocol and to Good Clinical Practice, the progress of enro llment, 
and to ensure that study  treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 

[COMPANY_001] Confidential Page 54
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
visits. Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA organization. Additionally , a central analy tics organization may  analyze data & 
identify  risks & trends for site operational parameters, and provide reports to [COMPANY_001] clinical 
teams to assist with trial oversi ght.
The Investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject’s file. The Investigator must also keep the original informed consent form signed by [CONTACT_1560] (a signed cop y is given to the subject).
The Investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No infor mation in source documents about the identity  of the 
subjects will be disclosed.
[ADDRESS_834533] udy will be anal yzed and reported.
Any data analysis carried out independently  by [CONTACT_626255].
12.1 Analysis sets
The Full Anal ysis Set (FAS) will be comprised of all randomized patients w ho meet both of 
the following criteria: 
Received at least one dose of study  treatment 
Have a baseline NPS score ≥ [ADDRESS_834534] been assigned to at the randomization. However, if patients received study  
treatment without being randomize d into the study  they  will be excluded from the FAS. 
The Safet y Anal ysis Set (SAF) includes all subjects who received at least one dose of study 
treatment. Subjects will be analyzed according to the study  treatment received, where treatment 
received is defined as the randomized/assigned treatment if the patient took at least one dose of 
that treatment or the first treatment received if the randomized/assigned treatment was never 
received.
The anal ysis of the primary objectives will be performed on the FAS. The FAS will be used for 
the analysis of all other efficacy  variables. The SAF will be used in the analy sis of all safet y 
variables.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
12.[ADDRESS_834535] deviation (SD), median, minimum, and maximum will be presented. For selected 
parameters, 25th and 75th percentiles will also be presented.
Relevant medical histories and current medical conditions at baseline will be summarized by 
[CONTACT_6657], by  [CONTACT_1570].
12.[ADDRESS_834536] 
deviation, median, 25th and 75th percentiles, minimum, and maximum will be presented.
The duration of exposure (expressed in weeks), the dose intensity  (computed as the ratio of 
actual cumulative dose received and actual duration of exposure) and the relative dose intensity 
(computed as the ratio of dose intensity  and planned dose intensity ) will be summarized by 
[CONTACT_64161].
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuatio n) and the corresponding reasons will be summarized for the study  treatment. 
Compliance with study  medication over the course of the entire study  will be summarized as 
the percentage of days with study  medication intake during the period from first intake to last 
intake.
All fevipi[INVESTIGATOR_626211].
Concomitant medications and significant non-drug therapi[INVESTIGATOR_49344] (ATC) classification sy stem in the Safety  Anal ysis Set.
Concomitant nasal poly p related medications will be summarized by  [CONTACT_094]-defined category .
12.4 Analysis of the primary  endpoint(s)
The primary  aim of the study  is to evaluate a change in nasal polyp size with fevipi[INVESTIGATOR_105169] (150 
mg or 450 mg once daily, separatel y) as compared to placebo. This will be evaluated by  [CONTACT_626256] (NPS) which is assessed by [CONTACT_626257] . The total NPS is recorded as the sum of the right and left nostril scores with a range of 
0 to 8 . A decrease in the NPS is considered a favorable outcome.
The analysis of the primary  endpoint will be conducted according to the intention to treat 
principle using FAS population.

[COMPANY_001] Confidential Page 56
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
12.4.1 Definition of primary  endp oint(s)
The primary  endpoint for this study  is the mean change in terms of reduction in polyp size as 
measured by [CONTACT_626218] (NPS) from baseline to week 16, for patients treated with 
fevipi[INVESTIGATOR_105169] (150 mg or 450 mg once dail y, separately) as compa red to placebo.
12.4.2 Statistical model, hypothesis, and method of analy sis
The primary  endpoint for this study  is the efficacy  in terms of change from baseline in the nasal 
polyp score of fevipi[INVESTIGATOR_105169] 450 mg plus SoC and fevipi[INVESTIGATOR_105169] 150 mg plus SoC over placebo plus 
SoC. The primary  null hy potheses are:
H0 450: the reduction in the polyp size at 16 weeks from the baseline as measured b y the 
NPS in fevipi[INVESTIGATOR_105169] 450 mg QD plus the SoC is less than or equal to the reduction in the 
polyp size as measured by  [CONTACT_218757] i n placebo plus the SoC for the population.
H0 150: the reduction in the polyp size at 16 weeks from the baseline as measured b y the 
NPS in fevipi[INVESTIGATOR_105169] 150 mg QD plus the SoC is less than or equal to the reduction in the 
polyp size as measured by  [CONTACT_626258].
The primary  alternative hy potheses are:
HA 450 : the reduction in the poly p size at 16 weeks from the baseline as measured by  [CONTACT_626259][INVESTIGATOR_105169] 450 mg QD plus the SoC is greater than the reduction of the poly psize 
as measured b y the NPS in placebo plus the SoC for the population
HA 150: the reduction in the polyp size at 16 weeks from the baseline as measured b y the 
NPS in fevipi[INVESTIGATOR_105169] 150 mg QD plus the SoC is greater than the reduction of the poly p size 
as me asured b y the NPS in placebo plus the SoC for the population
Family wise Ty pe I error rate control
The family wise type I error rate will be controlled at a 1-sided 2.5% level across the primar y 
null hypothesis using graphical approach specified by [CONTACT_105287] 12-1 (Bretz et al 2011). The 
Dunnett test will be used to test H [ADDRESS_834537] Hy potheses

[COMPANY_001] Confidential Page 57
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Vertices with associated weights denote the individual null hypotheses and their local 
significance levels (initially  the alpha is split 50%:50% across the primary  null hypotheses 
regarding the two dose levels. Directed edges between the vertices specify  how the local 
significance levels are propagated in case of significant results.
Statistical model for primary variable
The primary  efficacy  endpoint is mean change in nasal poly p score from baseline to Week 16.
Baseline NPS is defined as the last measurement performed before the first dose of study drug. 
The absolute change from baseline NPS values will be defined as the NPS at the timepoint 
minus the NPS at baseline.
The primary  efficacy  variable will be analyzed using a mixed model repeated measures 
(MMRM) approach (fevipi[INVESTIGATOR_105169] 450 mg plus SoC and fevipi[INVESTIGATOR_105169] 150 mg plus SoC). The model 
will include change from baseline to follow -up timepoints every  4 weeks through week 16 as 
response variables, fixed -effects factors for treatment, visit, treatment × visit interaction, nasal 
polyp score baseline value, and baseline × visit interaction. An unstructured correlation 
structure will be assumed for the repeated measures within patients. Parameters will be 
estimated using the restricted maximum likelihood method with the Newton -Raphson 
algorithm. The least square mean change in nasal polyp score from baseline to week 16 
alongside with 95% confidence interval and the P-value corresponding to the least square mean 
differenc e will be presented. The change in the least square mean will also be plotted against 
the visits to look at the general trend of the values across the visits.
The absolute change from baseline in NPS will be summarized by  [CONTACT_106865]
12.4.3 Handli ng of missing values/censoring/discontinuations
Despi[INVESTIGATOR_105201] -up for all patients, some patients may not be 
followed for nasal polyp size for the whole planned study  duration of 16 weeks. The primary 
analysis will be done using a Mixed Model Repeated Measures (MMRM) approach. Under the 
assumption that the missing values are missing at random (MAR), this provides asymptoticall y 
unbiased and consistent estimates of the treatment effects.
12.4.4 Sensitivity and Supportive analy ses
Sensitivity Analysis 1:A responder analysis of patients achieving a reduction of at least 1 in 
the Nasal Polyp score would be performed using a logistic regression, including terms for 
treatment, visits and interaction between treatment and visit. 
Sensitiv ity Analysis 2: The primary  efficacy  endpoint will be evaluated using the MMRM 
approach after imputing the Nasal Polyp Scores following surgery , only for patients who are 
considered as study  withdrawals due to undergoing 
surgical procedures, by [CONTACT_626260] (LOCF) technique. All other missing values will be imputed under 
the MAR approach within the MMRM model.
Sensitivity Analysis 3: The primary  efficacy  endpoint will be evaluated using the MMRM 
approach after imputing the Nasa l Polyp Scores following surgery  only for patients who are 
considered as study  withdrawals due to undergoing 
surgical procedures, by [CONTACT_626261] 58
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
observed score for that patient. All other missing values will be imputed under the MAR 
approach within the MMRM model.
12.5 Analysis of secondary  endpoints
The secondary  objectives include:
To evaluate the effect of symptoms as measured by [CONTACT_626262][INVESTIGATOR_105169] (150 mg or 450 mg once daily, separately) as compared to placebo, in terms of  
reduc tion in NCS from baseline to week 16.
Nasal congestion is defined as the objective restriction of the nasal cavity  airflow caused by 
[CONTACT_626263]. The nasal congestion score is calculated based on the responses from the patients in 
Question 1 from the nasal congestion questionnaire outlined in Section 16.4. The questionnaire 
has four questions relating to the symptoms of nasal obstruction with each question having four 
categories ranging from 0
-3, where the scores relate to the degree of severity  as follows:
0 = Not at all
1 = Mild
2 = Moderate
3 = Severe
The score however is calculated based on the response to the first question in the questionnai re.
The change in Nasal Congestion Score (NCS) will be analy zed using an MMRM model with 
visit, treatment, interaction between visit and treatment and the baseline average NCS as 
covariates. The least square mean change in Nasal Congestion Score from basel ine to week 16 
alongside with 95% confidence interval and the P-value corresponding to the least square mean 
difference will be presented.
To evaluate the effect on quality of life as measured by [CONTACT_626264]-nasal outcome test (SNOT -
22) with fevipi[INVESTIGATOR_105169] (150 mg or 450 mg once daily, separately) , compared to placebo, in 
terms of increase in QoL score from baseline to Week 16.
SNOT-22 measures the quality  of life in patients facing nasal obstructions (Section 16.5). There 
are 22 items available on the questionnaire. Each item in the questionnaire are followe d by [CONTACT_626265]:
0 = No problem
1 = Very  Mild Problem
2 = Mild or slight Problem
3= Moderate problem
4 = Severe Problem
5 = Problem as bad as it can be.
The scores for each of the items are added to get a total out of 110, with [ADDRESS_834538] important items affecting their health which are analy zed separatel y to give a rating across 
the patients The treatment group difference in terms of change from baseline at Week 16 in 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
SNOT- 22 will be estimated using an MMRM model with change from baseline as the response 
variable, adjusted for visits (Week 4, 8, 12 and 16), treatment, interaction between visit and 
treatment and baseline SNOT -
22.
The least square mean change in SNOT-22 Score from baseline to week 16 alongside with 95% 
confidence interval and the P-value corresponding to the least square mean differe nce will be 
presented.
To evaluate the effect on smell as measured by [CONTACT_626266] (UPSIT) with fevipi[INVESTIGATOR_105169] (150 mg or 450 mg, once daily) ,compared to 
placebo, in terms of increase in smell score from baseline t o Week 16.
The universit y of Pennsy lvania smell identification test (UPSIT) is a test for smell identification 
to test an individuals olfactory  response. The test is a measure of an individual's ability  to detect 
odor. It consists of 4 workbooks of 10 ques tions, giving a total of 40 questions. On each page, 
there is a different "scratch and sniff" strip which are embedded with a microencapsulated 
odorant. There is also a four choice multiple choice question on each page. The scents are 
released using a penc il. After each scent is released, the patient smells the level and detects the 
odor from the four choices. There is an answer column on the back of the test booklet, and the 
test is scored out of 40 items. The score is compared to scores in a normative database from 
4000 normal individuals, this tells the level of absolute smell function. The score also indicates 
how the patient does in accordance to their age group and gender. The maximum score 
achievable on the scale is 40.
The treatment group difference in terms of change from baseline at Week 16 in UPSI T will be 
estimated using an MMRM model with change from baseline as the response variable, adjusted 
for visits (week 4, 8, 12 and 16), treatment, interaction between visit and treatment and baseline 
UPSI T. The least square mean change in UPSI T Score from baseline to week 16 alongside with 
95% confidence interval and the P-value corresponding to the least square mean difference will 
be presented.
To evaluate the general safety and tolerability of fevipi[INVESTIGATOR_626212] t (150 mg and 450 mg, 
separately) as compared to placebo.
Safety  and tolerabilit y assessments were based on the incidence of adverse events and serious 
adverse events, as well as vital signs, clinical laboratory  evaluation, and 12-lead 
electrocardiogram fi ndings.
12.5.[ADDRESS_834539] intake 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
of the study  drug will be classified as a prior adverse event and not included in tabulations of 
treatment emergent adverse events.
The following treatment emergent adverse event summaries will be produ ced,
overall b y system organ class and preferred term,
overall b y system organ class and preferred,
overall b y system organ class, preferred term and maximum severity ,
suspected drug related adverse events by  [CONTACT_6657], and
adve rse events leading to permanent discontinuation of study  drug b y system organ class 
and preferred term.
Serious adverse events, non-serious adverse events, adverse events requiring dose adjustment 
or study -drug interruption adverse events requiring additio nal therapy  during the on -treatment 
period will be summarized.
The adverse events of special interest (AESI) will be listed and summarized by [CONTACT_1570].
Vital signs
All vital signs data will be listed by [CONTACT_1570], On-treatment notable vital signs 
abnormalities will be summarized by  [CONTACT_1570].
12-lead ECG
The notable ECG abnormalities will be summarized for following ECG variables,QT interval, 
RR interval, PR interval, QRS duration, heart rate, and Friedericia’s QTc. 
Clinical laboratory evaluations
All laboratory  data will be listed with abnormal values flagged.
All laboratory  parameter values will be classified into one of the four mutually  exclusive groups 
(low, normal, high, and low + high).
For selected laboratory  parameters, the numb er and percentage of patients with newl y occurring 
or worsening on-treatment laboratory  abnormalities meeting the clinically  notable will be 
summarized by [CONTACT_105294]-point over the treatment period, considering 
all post-baseline data from scheduled, unscheduled and premature discontinuation visits. 
Patients with any newly occurring or worsening on-treatment value meeting the clinically 
notable criteria will be counted under the applicable criteria.
12.7 Interim analy ses
No formal interim anal ysis will be performed in this trial.

[COMPANY_001] Confidential Page 61
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
Based on clinical judgement a mean reduction of 1.5 in polyp score (as measured by [CONTACT_626267]) can be expected with fevipi[INVESTIGATOR_105169] (450 mg and 150 mg) and SoC as compared to Placebo 
and SoC. Considering this factor, the sample size was calculated under an 80% p ower and 1.25% 
one sided alpha for comparison of each of the two dose levels of fevipi[INVESTIGATOR_626213]. A 10% dropout rate is considered as appropriate with reference to prior 
studies (omalizumab study  by [CONTACT_626268] 2013 and dupi[INVESTIGATOR_626214] 2016). 
From prior literature standard deviation of 1.8 is considered as appropriate for the change of 
score from baseline at 16 weeks in Nasal Poly p Score.
The
sample size calculation was performed using the software PASS 2008 using inequality  tests 
using difference of two independent means with equal variance.
The randomization will be performed in a 1:1:1 ratio for the two separate doses level of 
fevipi[INVESTIGATOR_105169] (450 mg and 150 mg) and the placebo arm. Under these assumptions (effect size = 
1.5, equal SD = 1.8,power = 80% for each arm individually , one- sided alpha = 0.0125 and 
dropout = 10%), the total sample size y ielded was 93 with 31 patients in each arm.
The sample size provides a power of 80% for each comparison but since we will be testing 
correlated hy pothesis using a Dunnet's test, this is a lower bound on the power. The real power 
is expected to be higher if in at least one of the [ADDRESS_834540] size (in other words, keepi[INVESTIGATOR_626215] 1.8 in 
each group) is equal to the clinicall y significant value of 1.[ADDRESS_834541] size is equal to 1.5 in both of the groups, the 
power will be substantially  higher i.e. around 93%
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implement ed, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Decla ration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the Investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the Investigator is required to sign a protocol signature [CONTACT_5389]/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to 
[COMPANY_001] monitors, auditors, [COMPANY_001] Qualit yAssurance representatives, designated agents of 
[COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
is requested by a regulatory  authority , the Investigator must inform [COMPANY_001] immediately  that 
this request has been made.
13.[ADDRESS_834542]. In addition, after study  completion ( defines as last patient last visit ) 
and f inalization of the study  report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the [COMPANY_001] clinical trial 
results website and all required Health Authority  websit es (e.g. Clinicaltrials.gov, EudraCT 
etc.) .
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy  training materials that were provided to you at the trial Investigator 
meetings
13.[ADDRESS_834543] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures (SOPs) as well as applicable global/local GCP regulations and ICH 
Guidelines.
Audits of Investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes
[ADDRESS_834544] be 
considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC and health authorities, where required, it cannot be 
implemented.

[COMPANY_001] Confidential Page 63
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
14.[ADDRESS_834545] be appro ved by [CONTACT_626269], and the IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the Investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represe nts a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Confidential Page 64
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
[ADDRESS_834546]
Bachert C, Mannent L, Nacleri o RM, et al (2016) Effect of Subcutaneous Dupi[INVESTIGATOR_626216] p Burden in Patients With Chronic Sinusitis and Nasal Poly posis: A Randomized 
Clinical Trial. JAMA p. 469 -79.
Bretz F, Posch M, Glimm E, et al (2011) Graphical approaches for multiple compari son 
procedures using weighted Bonferroni, Simes, or parametric tests. Biom J p. [ADDRESS_834547] F, et al (2011) Reslizumab for poorly  controlled, eosinophilic 
asthma: a randomized, placebo -controlled stud y. Am. J. Respir. Crit. Care Med. p. 1125-32.
Castro M, Zangrilli J, Wechsler ME, et al (2015) Reslizumab for inadequately  controlled 
asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double -
blind, randomised, placebo- controlled, phase 3 trials. Lan cet Respir Med p. 355-66.
Chevalier E, Stock J, Fisher T, et al (2005) Cutting edge: chemoattractant receptor-
homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and 
eosinophil recruitment. J. I mmunol. p. 2056-60.
Deng JW , Song I S, Shin HJ, et al (2008) The effect of SL CO1B1*15 on the disposition of 
pravastatin and pi[INVESTIGATOR_105205]: the contribution of transporting activity  
changes b y SLCO1B1*15. Pharmacogenet. Genomics p. 424 -33.
Elsby  R, Hilgendorf C, Fenner K (2012) Understanding the critical disposition pathway s of 
statins to assess drug- drug interaction risk during drug development: it's not just about 
OATP1B1. Clin. Pharmacol. Ther. p. 584 -98.
Gevaert P, Calus L, Van Zele T, et al (2013) Omalizumab is effective in allergic and 
nonallergic patients with nasal poly ps and asthma. J. Allergy  Clin. Immunol. p. 110- 6.e1.
Jacobson TA (2008) Toward "pain-free" statin prescribing: clinical algorithm for diagnosis 
and management of my algia. May o Clin. Proc. p. 687-700.
Juniper EF, O'By [CONTACT_21143], Guy att GH, et al. 1999. Development and validation of a 
questionnaire to measure asthma control. Eur. Respir. J.. 14(4):902
-7.
Juniper EF, Svensson K, Mörk AC, et al (2005) Measurement properties and interpretation of 
three shortened versions of the asthma control questionnaire. Respir Med p. 553 -8.
Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br. J. 
Pharmacol. p. 693 -705.
Larsen K The clinical relationship of nasal poly ps to asthma. Allerg y Asthma Proc p. 243 -9.
Mjösberg JM, Trifari S, Crellin NK, et al (2011) Human IL -25- and IL - 33- responsive t ype 2 
innate ly mphoid cells are defined by  [CONTACT_626270]2 and CD161. Nat. I mmunol. p. 
1055-62.
Newton JR, Ah -See KW (2008) A review of nasal po
lyposis. Ther Clin Risk Manag p. 507-
12.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Noé J, Portmann R, Brun ME, et al (2007) Substrate- dependent drug -drug interactions 
between gemfibrozil, fluvastatin and other organic anion -transporting peptide (OATP) 
substrates on OATP1B1, OATP2B1, and OATP1B3. D rug Metab. Dispos. p. 1308 -14.
Orlandi RR, Kingdom TT, Hwang PH, et al (2016) International Consensus Statement on 
Allergy  and Rhinology : Rhinosinusitis. I nt Forum Allergy  Rhinol p. S22 -209.
Pavord ID, Korn S, Howarth P, et al (2012) Mepolizumab for severe eosinophilic asthma 
(DREAM): a multicentre, double- blind, placebo -controlled trial. Lancet p. 651-9.
Pérez -Novo CA, Holtappels G, Vinall SL , et al (2010) CRTH2 mediates the activation of 
human Th2 cells in response to PGD(2) released from IgE/anti -IgE treated nasal poly p tissue. 
Allergy  p. 304 -10.
 
Regan SL, Maggs JL , Hammond TG, et al (2010) Acy l glucuronides: t he good, the bad and 
the ugl y. Biopharm Drug Dispos p. 367-95.
Shaw JL , Ashoori F, Fakhri S, et al I ncreased percentage of mast cells within sinonasal 
mucosa of chronic rhinosinusitis with nasal poly p patients independent of atopy . Int Forum 
Allergy Rhinol p. 233- 40.
Yamamoto M, Okano M, Fujiwara T, et al (2009) Expression and characterization of PGD2 
receptors in chronic rhinosinusitis: modulation of DP and CRTH2 by  [CONTACT_626271]2. I nt. Arch. 
Allergy  Immunol. p. 127
-36.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16 Appendices
16.1 Appendix 1: Clinically  notable labo ratory  values and vital signs
The central laboratory  will flag laboratory  values falling outside of the normal ranges on the 
central laboratory  reports. Investigators are responsible for reviewing these abnormal values for 
clinical significance, signing the laboratory  reports to indicate their review, and reporting values 
considered clinically  significant in the appropriate electronic case report form (eCRF).
Any clinicall y significant abnormal laboratory  value should be evaluated and followed-up by 
[CONTACT_626272] a cause for the abnormality  is determined.
See Section 16.[ADDRESS_834548] trigger definitions and follow -
up requirements. See Section 16.3 for specific renal alert criteria and actions.
For electrocardiograms (ECGs), a notable QTc value is defined as a QTcF (Fridericia) interval 
of ≥450 msec for males or ≥460 msec for females. All ECGs will be assessed locally at site and 
with assessment of clinical relevance and continuance of the patient being confirmed by [CONTACT_3786].

[COMPANY_001] Confidential Page 67
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.2 Appendix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY 
TRIGGERS[ADDRESS_834549] < ALT / AST ≤ [ADDRESS_834550]
1.[ADDRESS_834551] < TBL ≤ [ADDRESS_834552]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and TBL > 2 × 
ULN [mainly conjugated fraction] without notable increase in ALP to > 2 × 
ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, abdominal 
pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms TBL=total 
bilirubin; ULN=upper limit of normal
Table 16-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law caseaDiscontinue the study treatment immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
ALT or AST
> 8 × ULN Discontinue the study treatment immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
> 3 × ULN and INR > 1.5 Discontinue the study treatment immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -up 
monitoring
If elevation persists for more than 2 weeks, 
discontinue the study drug
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)

[COMPANY_001] Confidential Page 68
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Criteria Actions required Follow -up monitoring
> 3 × ULN accompanied by 
[CONTACT_18688]Discontinue the study treatment immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
> 3 to ≤ 5 × ULN (patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patien tInvestigator discretion
Monitor LFT within 1 to 4 
weeks
ALP (isolated)
> 2 × ULN (in the absence 
of known bone pathology)Repeat LFT within 48 hours
If elevation persists, establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
TBL (isolated)
> 2 × ULN (in the absence 
of known Gilbert 
syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the study d rug 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
Test for hemolysis (e.g., 
reticulocytes, 
haptoglobin, 
unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN (patient 
is asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observa tion of the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice Discontinue the study treatment immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFALT, AST, TBL, Alb, 
PT/INR, ALP and γGT 
until resolutionc
(frequency at Investigator 
discretion)
Any AE potentially 
indicative of a liver toxicityConsider study treatment interruption or 
discontinuation
Hospi[INVESTIGATOR_626217]
Establish causality
Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in the appropriate CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN b(Gene ral) 
malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia cResolution is defined as an 
outcome of one of the following: (1) return to baseline values, (2) stable values at three subsequent monitoring 
visits at least 2 weeks apar t, (3) remain at elevated level after a maximum of 6 months, (4) liver transplantation, 
and (5) death.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.3 Appendix 3: Specific Renal A lert Criteria and A ctions and Event 
Follow -up
Table 16-3 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase 25 –49% compared to 
baselineConfirm 25% increase after 24 -48h
Follow up within 2 -5 days
Acute Kidney Injury: Serum creatinine incr ease 
≥50% compared to baselineFollow up within 24 -48h if possible
Consider study treatment interruption
Consider patient hospi[INVESTIGATOR_059] /specialized treatment
Urine Event
Albumin -creatinine ratio (ACR) ≥1g/g or ≥100 
mg/mmol;
Protein -creatinine ratio (PCR ) ≥1g/g or ≥100 
mg/mmolConfirm value after 24 -48h
Perform urine microscopy
Consider study treatment interruption / or 
discontinuation
For all renal events:
Document contributing factors in the CRF : co-medication, other co -morbid conditions, and add itional diagnostic 
procedures performed
Monitor patient regularly (frequency at investigator’s discretion) until either:
Event resolution: sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline, or
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio stabilization at a 
new level with ±50% variability over last 6 months.

[COMPANY_001] Confidential Page 70
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.4 Appendix 4: Nasal Congestion Score Questionnaire
Figure 16-1 Nasal Congestion Score

[COMPANY_001] Confidential Page 71
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.5 Appendix 5: SNOT -22 Questionnaire
Figure 16-2 SNOT -22 Questionnaire

[COMPANY_001] Confidential Page 72
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.6 Appendix 6: A CQ-5 Questionnaire
Figure 16-3 Asthma Control Questionnaire -5 -Page 1

[COMPANY_001] Confidential Page 73
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
Figure 16-4 Asthma Control Questionnaire -5 -Page 2

[COMPANY_001] Confidential Page 74
Amended Protocol Version 03(Clean ) Protocol No. CQAW 039A2322
16.7 Appendix 7: Nasal Endoscopy
Nasal Endoscope will be performed at the clinic using either a flexible fiber optic endoscope or 
a rigid endoscope. Pol yps will be evaluated using the following scale:
Poly p Score Poly p Size
0 No polyps
1 Small polyps in the middle meatus not reaching below the inferior border of the middle 
turbinate
2 Polyps reaching below the lower border of the middle turbinate
3 Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle
turbinate
4 Large polyps causing complete obstruction of the inferior nasal cavity
Note: Scoring system is used to evaluate polyp size in each nasal passage by [CONTACT_626273] y. Nasal polyp score is the sum of unilateral polyp scores for each nasal 
passage.The scoring is modified to accommodate patients who have had a middle turbinectomy , 
such that the poly p must reach the top of the inferior turbinate to be graded as Score 2.
If the patient has polyps between the middle turbinate and septum meaning that polyps are 
coming from posterior ethmoid cells, one point was added, but not if the polyp scale was alread y 
confirmed. The grade of polyps in each nasal cavity of all patients will be taken into account in 
the results.
A video of each endosc opy will be recorded and initially  saved locally  within the clinical site. 
For endoscopy  procedures performed at screening, the initial assessment of eligibility  will be 
performed locall y by [CONTACT_626274] t of the 
NPS and confirmation of eligibility  by [CONTACT_18014]. This should be confirmed before the 
patient enters the run-in period. The endoscop y will be assessed at the end of the run-in with 
baseline NPS assigned locally  by [CONTACT_737] . Should the Investigator deem the patient 
eligible for randomization then the baseline video will be uploaded for central reading 
assessment. The final result from the central readers must be received to re-confirm eligibility , 
prior to randomization. Upon confirmat ion of eligibility , the endoscop y assessments from 
Treatment Day  [ADDRESS_834553] as adjudicator and will make the final decision on the 
NPS.
Full training on the use of the vendors cloud based sy stem will be provided.
